<?xml version='1.0' encoding='UTF-8'?>
<!-- Created by Xince -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:vine="http://VINE/20250930" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025">
  <link:schemaRef xlink:href="./VINE_taxonomy_Q3_2024_2025.zip/VINE_taxonomy_Q3_2024_2025/VINE-20251231.xsd" xlink:type="simple"/>
  <xbrli:context id="c">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-10-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-03-14</xbrli:startDate>
      <xbrli:endDate>2023-03-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vine:DirectToConsumerRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-03-14</xbrli:startDate>
      <xbrli:endDate>2023-03-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-10-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-04-01</xbrli:startDate>
      <xbrli:endDate>2024-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesARedeemablePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-10-01</xbrli:startDate>
      <xbrli:endDate>2024-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c18">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="vine:MergerAxis">vine:MergerCompany2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-10-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c19">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-09-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c24">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vine:DirectToConsumerRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c26">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c32">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c33">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c34">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">vine:WholesaleConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c35">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c36">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vine:WholesaleRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c37">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c38">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c39">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c40">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c41">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c42">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c43">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c44">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vine:DirectToConsumerRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c45">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c46">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c47">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c48">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c49">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">vine:WholesaleConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c50">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c51">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-09-08</xbrli:startDate>
      <xbrli:endDate>2023-09-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c52">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c53">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c54">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c55">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c56">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c57">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c58">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">vine:WholesaleConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c59">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c60">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveVicePresidentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c61">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c62">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c63">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c64">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c65">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c66">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveVicePresidentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c67">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c68">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vine:DirectToConsumerRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c69">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c70">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="vine:MergerAxis">vine:MergerCompany1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-10-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c71">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveVicePresidentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c72">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c73">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c74">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">vine:WholesaleConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c75">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c76">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveVicePresidentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c77">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c78">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c79">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c80">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c81">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c82">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c83">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c84">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c85">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c86">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c87">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c88">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c89">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c90">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c91">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c92">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c93">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c94">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c95">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-03-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c96">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c97">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-03-14</xbrli:startDate>
      <xbrli:endDate>2024-03-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c98">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c99">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-04-01</xbrli:startDate>
      <xbrli:endDate>2024-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c100">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-11-01</xbrli:startDate>
      <xbrli:endDate>2023-11-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c102">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-04-01</xbrli:startDate>
      <xbrli:endDate>2024-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c103">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c104">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-04-01</xbrli:startDate>
      <xbrli:endDate>2024-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c105">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-04-01</xbrli:startDate>
      <xbrli:endDate>2024-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-04-01</xbrli:startDate>
      <xbrli:endDate>2024-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c108">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="vine:AgreementAxis">vine:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vine:AgreementAxis">vine:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vine:LicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vine:LicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c112">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vine:WholesaleRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c114">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c116">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vine:LicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c117">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c118">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vine:WholesaleRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c119">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c120">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vine:LicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c121">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c122">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c123">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c124">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="vine:AgreementAxis">vine:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c126">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c127">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c128">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vine:AgreementAxis">vine:SponsorshipAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c132">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-10-01</xbrli:startDate>
      <xbrli:endDate>2024-11-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c133">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="vine:AgreementAxis">vine:SponsorshipAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c134">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c135">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-10-01</xbrli:startDate>
      <xbrli:endDate>2024-11-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c136">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c137">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c138">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c139">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-11-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c140">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c141">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c142">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c143">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c144">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c145">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c146">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c147">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c148">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c149">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c150">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c151">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c152">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c153">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c154">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-12-01</xbrli:startDate>
      <xbrli:endDate>2023-12-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c155">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c156">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c157">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vine:VendorStockAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c158">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c159">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c160">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c161">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c162">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c163">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-03-01</xbrli:startDate>
      <xbrli:endDate>2023-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c164">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c165">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-03-01</xbrli:startDate>
      <xbrli:endDate>2024-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c166">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-09-07</xbrli:startDate>
      <xbrli:endDate>2023-09-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c167">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c168">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c169">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vine:VendorStockAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c170">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vine:VendorStockAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c171">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vine:MrMichaelsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-01-25</xbrli:startDate>
      <xbrli:endDate>2024-01-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c172">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-27</xbrli:startDate>
      <xbrli:endDate>2023-07-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c173">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-02</xbrli:startDate>
      <xbrli:endDate>2023-08-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c174">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c175">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c176">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c177">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vine:WholesaleRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c178">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c179">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c180">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vine:SeriesARedeemablePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c181">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-02-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c182">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c183">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vine:LicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-07-01</xbrli:startDate>
      <xbrli:endDate>2024-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c184">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-03-14</xbrli:startDate>
      <xbrli:endDate>2023-03-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c185">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vine:LicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="usd">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="usd1">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <vine:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresWeightedAverageExercisePrice id="f" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:IncreaseDecreaseInInventories id="f1" decimals="0" contextRef="c1" unitRef="usd1">1221304.0</us-gaap:IncreaseDecreaseInInventories>
  <vine:SecuritiesPurchaseAgreementConvertibleNoteWarrants id="f2" decimals="INF" contextRef="c2" unitRef="shares">740000.0</vine:SecuritiesPurchaseAgreementConvertibleNoteWarrants>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="f3" decimals="0" contextRef="c3" unitRef="usd1">122068.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f4" decimals="0" contextRef="c4" unitRef="usd1">3143969.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:OperatingIncomeLoss id="f5" decimals="0" contextRef="c5" unitRef="usd1">-2400891.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:SharesOutstanding id="f6" decimals="INF" contextRef="c6" unitRef="shares">15976227.0</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f7" decimals="INF" contextRef="c7" unitRef="shares">940.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="f8" decimals="0" contextRef="c1" unitRef="usd1">2615014.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:Revenues id="f9" decimals="0" contextRef="c8" unitRef="usd1">55443.0</us-gaap:Revenues>
  <us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds id="f10" decimals="0" contextRef="c9" unitRef="usd1">3140000.0</us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds>
  <us-gaap:EarningsPerShareDiluted id="f11" decimals="INF" contextRef="c1" unitRef="usd">-0.57</us-gaap:EarningsPerShareDiluted>
  <us-gaap:DividendsPreferredStock id="f12" decimals="0" contextRef="c10" unitRef="usd1">50000.0</us-gaap:DividendsPreferredStock>
  <vine:PromissoryNotePrincipalLoanReceivableAmount id="f13" decimals="0" contextRef="c11" unitRef="usd1">3500000.0</vine:PromissoryNotePrincipalLoanReceivableAmount>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f14" decimals="INF" contextRef="c10" unitRef="shares">15976227.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensation id="f15" decimals="0" contextRef="c1" unitRef="usd1">1734765.0</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures id="f16" xsi:nil="true" contextRef="c" unitRef="shares"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f17" decimals="0" contextRef="c12" unitRef="usd1">714692.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <vine:SponsorshipAgreementsCurrent id="f18" decimals="0" contextRef="c13" unitRef="usd1">608818.0</vine:SponsorshipAgreementsCurrent>
  <vine:PricePerShareOfRedemptionPercentage id="f19" decimals="INF" contextRef="c14" unitRef="pure">1.5</vine:PricePerShareOfRedemptionPercentage>
  <us-gaap:ProceedsFromFeesReceived id="f20" decimals="0" contextRef="c1" unitRef="usd1">2600000.0</us-gaap:ProceedsFromFeesReceived>
  <vine:SecuritiesPurchaseAgreementConvertibleNoteOriginalIssueDiscountRate id="f21" decimals="INF" contextRef="c15" unitRef="pure">0.2</vine:SecuritiesPurchaseAgreementConvertibleNoteOriginalIssueDiscountRate>
  <us-gaap:Revenues id="f22" decimals="0" contextRef="c5" unitRef="usd1">238261.0</us-gaap:Revenues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="f23" decimals="INF" contextRef="c16" unitRef="shares">20000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:StockholdersEquity id="f24" decimals="0" contextRef="c17" unitRef="usd1">-22252979.0</us-gaap:StockholdersEquity>
  <vine:SaleLeasebackTransactionGrossProceedInvestingActivities id="f25" decimals="0" contextRef="c5" unitRef="usd1">3930000.0</vine:SaleLeasebackTransactionGrossProceedInvestingActivities>
  <vine:PromissoryNoteInterestRatePerAnnum id="f26" decimals="INF" contextRef="c18" unitRef="pure">0.06</vine:PromissoryNoteInterestRatePerAnnum>
  <us-gaap:OtherLiabilitiesCurrent id="f27" decimals="0" contextRef="c13" unitRef="usd1">309333.0</us-gaap:OtherLiabilitiesCurrent>
  <vine:GrossProceedsFromSecuritiesPurchaseAgreement id="f28" decimals="0" contextRef="c15" unitRef="usd1">500000.0</vine:GrossProceedsFromSecuritiesPurchaseAgreement>
  <us-gaap:CashEquivalentsAtCarryingValue id="f29" decimals="0" contextRef="c13" unitRef="usd1">236340.0</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="f30" contextRef="c5">&lt;p id="xdx_80C_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zaFDB6uWVuSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_829_z4NNV30BM5Fb"&gt;9. EQUITY-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Shares of Restricted Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2023, the members of the Companys
Board of Directors, collectively, were granted a total of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230401__20230430__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4A1UvgemCjg"&gt;100,000&lt;/span&gt; shares of restricted stock. The vesting period is as follows: &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230401__20230430_zUsykjyZo7r7"&gt;25,000&lt;/span&gt;
shares vested immediately with &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20230930_zuoawr8PbPgi"&gt;25,000&lt;/span&gt; shares vesting each quarter following the award date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total equity-based compensation expense related to
shares of restricted stock issuances was $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240701__20240930__srt--TitleOfIndividualAxis__srt--ExecutiveVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhp3TrrIJOUh"&gt;0&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230701__20230930__srt--TitleOfIndividualAxis__srt--ExecutiveVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRPLWYXylpoj"&gt;105,346&lt;/span&gt; for the three months ended September 30, 2024 and 2023, respectively and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240930__srt--TitleOfIndividualAxis__srt--ExecutiveVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zetvvM1RAdwh"&gt;0&lt;/span&gt; and
$&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230930__srt--TitleOfIndividualAxis__srt--ExecutiveVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWGtAIZXQih3"&gt;598,404&lt;/span&gt; for the nine months ended September 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Restricted stock activity as of and for the nine-month
period ended September 30, 2024 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zQgvDPfVjg2d" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Restricted stock activity and vendor stock award activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_4B3_us-gaap--AwardTypeAxis_us-gaap--RestrictedStockMember_zUZbgVtJTLzg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;br/&gt; Shares of Restricted Stock&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43E_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_zWNaT4m7OJu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_pip0_dtY_c20231231__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgmQAwR6r3u5"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_zsXixXCfcyb4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_434_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_zwcFgGm3vpz" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested or released&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_zfVLW8qUFaph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0895"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_439_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_zYS71cw41yX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0897"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5tIcPErTiii"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Vendor Stock Awards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Vendor stock award activity subject to revenue-related
performance objectives during the nine months ended September 30, 2024 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_4BA_us-gaap--AwardTypeAxis_custom--VendorStockAwardsMember_zJBZKQZCiIVb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of Shares of Vendor Stock Awards&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Vesting&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_433_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_zmNBusOJzpyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;1,030,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_pip0_dtY_c20231231__20231231__us-gaap--AwardTypeAxis__custom--VendorStockAwardsMember_zZxciQUC68Dd"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43A_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_zejr6RWPBVil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_432_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_zgO5PgI7gPC" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested or released&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_435_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_zAI9gyCbxOrb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_431_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_zLVBKSdZh40j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,030,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_pip0_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__custom--VendorStockAwardsMember_zEXwQxqNPFX1"&gt;0.46&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zSJ3XWedR9Le" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock option activity for nine-month period ended
September 30, 2024 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeZ1yaPbxAWe" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock option activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240930_zCdsSkEgrWRc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;446,559&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_z6khs5NZxf2e"&gt;8.88&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pip0_dtY_c20231231__20231231_zpVXXBdadlx3"&gt;8.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240930_zCTlZsUwlHSd"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zXBDYcr8iHai"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240930_zUxSaHEjPFe4"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_z2hu4hgugFbk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0919"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240930_znnEDe59cCCa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,666&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240930_zl0DU1mKi5b"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240930_zhhmxoSFW9El" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;444,893&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_zdeL324TGwZ1"&gt;8.91&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pip0_dtY_c20240101__20240930_zc0yE7EBiqlj"&gt;7.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240930_z4NeqoLinr0d" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;69,892&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240930_z7WdflQv2fL8"&gt;3.04&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pip0_dtY_c20240101__20240930_zbQh03MZKAB5"&gt;7.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_ztN1USr0eOwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity-based compensation expense totaling $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5zgy9VJKZm6"&gt;1,626&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zilImyjaQdxk"&gt;6,504&lt;/span&gt; has been recognized relating to these stock options during the three months ended September 30, 2024 and 2023, respectively
and $&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqg9KxUlKU2e"&gt;4,877&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5dqNa3oISK6"&gt;145,295&lt;/span&gt; for the nine months ended September 30, 2024 and 2023, respectively. The total unrecognized equity-based compensation
expense was $&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240930_zLhB6FZywRkf"&gt;1,381&lt;/span&gt; as of September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As disclosed in Note 8, &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230301__20230331_zOhuhQ8wUlm7"&gt;3,143,969&lt;/span&gt; warrants were granted
as part of the Rights Offering in March 2023. Also noted in Note 8, &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240301__20240331_zzz34OVPU1Z9"&gt;300,000&lt;/span&gt; warrants were granted in March 2024 to our financial advisor
and placement agent in connection with our offering and sale of Series B Preferred Stock. In September 2024 the Company issued &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240901__20240930_zMqxIsa1qAf5"&gt;444,000&lt;/span&gt;
warrants in connection with the convertible notes described in Note 7.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Warrant activity for nine-month period ended September
30, 2024 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHWzx5Heq3Ca" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrant activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_4B0_us-gaap--AwardTypeAxis_us-gaap--WarrantMember_zGJdCkCTnoTk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43A_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zDUOGWop4lzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 51%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;3,553,969&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj57EWuGYKLk"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_pip0_dtY_c20231231__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcdkwPhEmbf2"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zFYmt2dxMuXa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;744,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8CV1SmQbos2"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageRemainingContractualTerm_pip0_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2ePUcuHcwaj"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested or released&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_430_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_zxABwxIn8eBb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPUmK5E13cs5"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_432_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_znuSn0C9ypy6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,997,969&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXXGpKrjsTzj"&gt;1.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_pip0_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYqk4QHgokWf"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zlfV7PX0Khc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes
option-pricing model to estimate the fair value of equity-based awards. The inputs for the Black-Scholes valuation model require
managements significant assumptions. Prior to the Companys IPO, the price per share of common stock was determined by
the Companys board based on recent prices of common stock sold in private offerings. Subsequent to the IPO, the price per
share of common stock is determined by using the closing market price on the New York Stock Exchange on the grant date. The
risk-free interest rate is based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately
equal to the expected life at the grant date. The expected term for employee and non-employee awards ranged from &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zydkXlhERwdc"&gt;5&lt;/span&gt;
to &lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_z3HcMqbt5V47"&gt;10&lt;/span&gt;
years based on industry data, vesting period, contractual period, among other factors. The expected volatility was estimated
based on historical volatility information of the Company. The Company does not expect to pay dividends. For awards with a performance
condition, stock compensation is recognized over the requisite service period if it is probable that the performance condition will
be satisfied.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="f31" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:OtherNonoperatingIncomeExpense id="f32" decimals="0" contextRef="c5" unitRef="usd1">39.0</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:StockholdersEquity id="f33" decimals="0" contextRef="c19" unitRef="usd1">25631255.0</us-gaap:StockholdersEquity>
  <vine:GrossProceedsFromSecuritiesPurchaseAgreement id="f34" decimals="0" contextRef="c20" unitRef="usd1">300000.0</vine:GrossProceedsFromSecuritiesPurchaseAgreement>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f35" decimals="0" contextRef="c3" unitRef="usd1">981763.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:SettlementLiabilitiesCurrent id="f36" decimals="0" contextRef="c3" unitRef="usd1">585976.0</us-gaap:SettlementLiabilitiesCurrent>
  <us-gaap:SharesOutstanding id="f37" decimals="INF" contextRef="c21" unitRef="shares">10000.0</us-gaap:SharesOutstanding>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f38" decimals="0" contextRef="c5" unitRef="usd1">2393735.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="f39" contextRef="c5">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhtXokoxSjJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zqYvL0LtpBvb"&gt;Application of New or Revised Accounting
Standards&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Jumpstart Our Business Startups Act
of 2012 (the JOBS Act), a company constituting an emerging growth company is, among other things, entitled
to rely upon certain reduced reporting requirements and is eligible to take advantage of an extended transition period to comply with
new or revised accounting standards applicable to public companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is an emerging growth company and has
elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates
for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively
and irrevocable opts out of the extended transition period provide in the JOBS Act.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <vine:SecuritiesPurchaseAgreementConvertibleNoteConversionPrice id="f40" decimals="INF" contextRef="c15" unitRef="usd">0.4</vine:SecuritiesPurchaseAgreementConvertibleNoteConversionPrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="f41" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f42" decimals="0" contextRef="c22" unitRef="usd1">26572493.0</us-gaap:StockholdersEquity>
  <us-gaap:CostOfRevenue id="f43" decimals="0" contextRef="c10" unitRef="usd1">65046.0</us-gaap:CostOfRevenue>
  <dei:EntityCentralIndexKey id="f44" contextRef="c5">0001880343</dei:EntityCentralIndexKey>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="f45" decimals="0" contextRef="c23" unitRef="usd1">859946.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <dei:AmendmentFlag id="f46" contextRef="c5">false</dei:AmendmentFlag>
  <dei:DocumentQuarterlyReport id="f47" contextRef="c5">true</dei:DocumentQuarterlyReport>
  <us-gaap:StockholdersEquity id="f48" decimals="0" contextRef="c6" unitRef="usd1">15976.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f49" decimals="0" contextRef="c7" unitRef="usd1">1.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <vine:AccruedCreditCardChargesCurrent id="f50" decimals="0" contextRef="c3" unitRef="usd1">3580.0</vine:AccruedCreditCardChargesCurrent>
  <vine:SecuritiesPurchaseAgreementConvertibleNoteMaximumOutstandingSharesOwnership id="f51" decimals="INF" contextRef="c15" unitRef="pure">0.0999</vine:SecuritiesPurchaseAgreementConvertibleNoteMaximumOutstandingSharesOwnership>
  <vine:StockIssuedAndOutstanding id="f52" decimals="INF" contextRef="c14" unitRef="pure">0.75</vine:StockIssuedAndOutstanding>
  <dei:DocumentFiscalPeriodFocus id="f53" contextRef="c5">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:Revenues id="f54" decimals="0" contextRef="c24" unitRef="usd1">103427.0</us-gaap:Revenues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f55" decimals="INF" contextRef="c25" unitRef="shares">3553969.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <dei:DocumentFiscalYearFocus id="f56" contextRef="c5">2024</dei:DocumentFiscalYearFocus>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="f57" decimals="0" contextRef="c10" unitRef="usd1">50000.0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <dei:CurrentFiscalYearEndDate id="f58" contextRef="c5">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="f59" decimals="0" contextRef="c26" unitRef="usd1">750000.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <dei:EntityInteractiveDataCurrent id="f60" contextRef="c5">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntitySmallBusiness id="f61" contextRef="c5">true</dei:EntitySmallBusiness>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther id="f62" decimals="0" contextRef="c5" unitRef="usd1">-38646.0</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <dei:TradingSymbol id="f63" contextRef="c5">VINE</dei:TradingSymbol>
  <us-gaap:CommonStockSharesOutstanding id="f64" decimals="INF" contextRef="c13" unitRef="shares">15976227.0</us-gaap:CommonStockSharesOutstanding>
  <dei:EntityEmergingGrowthCompany id="f65" contextRef="c5">true</dei:EntityEmergingGrowthCompany>
  <us-gaap:ProceedsFromNotesPayable id="f66" decimals="0" contextRef="c5" unitRef="usd1">42500.0</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="f67" decimals="0" contextRef="c13" unitRef="usd1">336340.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:ScheduleOfDividendsPayableTextBlock id="f68" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDividendsPayableTextBlock_znzFEg4AnOlb" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued dividends that the Company is legally obligated to pay (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20240101__20240930_zdCzWuqNG8b" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49C_20230101__20231231_zxCYWQYCIBDb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December31,&lt;br/&gt; 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DividendsPreferredStockStock_zsxnvZHR6G8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify"&gt;Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;148,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;41,867&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDividendsPayableTextBlock>
  <us-gaap:OtherNotesPayableCurrent id="f69" xsi:nil="true" contextRef="c13" unitRef="usd1"/>
  <us-gaap:RepaymentsOfNotesPayable id="f70" decimals="0" contextRef="c5" unitRef="usd1">15000.0</us-gaap:RepaymentsOfNotesPayable>
  <vine:PromissoryNotePrincipalLoanReceivableAmount id="f71" decimals="0" contextRef="c18" unitRef="usd1">3500000.0</vine:PromissoryNotePrincipalLoanReceivableAmount>
  <us-gaap:ConvertibleNotesPayableCurrent id="f72" xsi:nil="true" contextRef="c13" unitRef="usd1"/>
  <us-gaap:Revenues id="f73" decimals="0" contextRef="c1" unitRef="usd1">1586714.0</us-gaap:Revenues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f74" decimals="INF" contextRef="c27" unitRef="shares">3997969.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <dei:EntityAddressAddressLine1 id="f75" contextRef="c5">P.O.     Box 78984</dei:EntityAddressAddressLine1>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f76" decimals="0" contextRef="c28" unitRef="usd1">1625.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:PreferredStockValue id="f77" xsi:nil="true" contextRef="c29" unitRef="usd1"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f78" decimals="INF" contextRef="c30" unitRef="shares">8000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <vine:StockIssuedAndOutstanding id="f79" decimals="INF" contextRef="c5" unitRef="pure">0.5</vine:StockIssuedAndOutstanding>
  <us-gaap:InventoryLIFOReserveEffectOnIncomeNet id="f80" xsi:nil="true" contextRef="c31" unitRef="usd1"/>
  <us-gaap:OperatingIncomeLoss id="f81" decimals="0" contextRef="c10" unitRef="usd1">-308968.0</us-gaap:OperatingIncomeLoss>
  <vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued id="f82" decimals="0" contextRef="c32" unitRef="usd1">3144.0</vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued>
  <vine:AccruedCreditCardChargesCurrent id="f83" decimals="0" contextRef="c13" unitRef="usd1">7275.0</vine:AccruedCreditCardChargesCurrent>
  <us-gaap:InventoryLIFOReserveEffectOnIncomeNet id="f84" xsi:nil="true" contextRef="c5" unitRef="usd1"/>
  <us-gaap:CommonStockSharesOutstanding id="f85" decimals="INF" contextRef="c3" unitRef="shares">15976227.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:InventoryLIFOReserveEffectOnIncomeNet id="f86" xsi:nil="true" contextRef="c1" unitRef="usd1"/>
  <us-gaap:OtherNonoperatingIncomeExpense id="f87" decimals="0" contextRef="c1" unitRef="usd1">1296.0</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:StockholdersEquity id="f88" decimals="0" contextRef="c33" unitRef="usd1">-26476760.0</us-gaap:StockholdersEquity>
  <vine:SecuritiesPurchaseAgreementConvertibleNoteWarrantsExercisePrice id="f89" decimals="INF" contextRef="c15" unitRef="usd">0.4</vine:SecuritiesPurchaseAgreementConvertibleNoteWarrantsExercisePrice>
  <vine:PricePerShareOfRedemptionPercentage id="f90" decimals="INF" contextRef="c5" unitRef="pure">2.0</vine:PricePerShareOfRedemptionPercentage>
  <us-gaap:OtherNonoperatingIncomeExpense id="f91" xsi:nil="true" contextRef="c10" unitRef="usd1"/>
  <us-gaap:ConvertibleNotesPayableCurrent id="f92" decimals="0" contextRef="c3" unitRef="usd1">174969.0</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f93" decimals="0" contextRef="c13" unitRef="usd1">1389257.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ConcentrationRiskPercentage1 id="f94" decimals="INF" contextRef="c34" unitRef="pure">0.123</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f95" decimals="INF" contextRef="c3" unitRef="shares">444893.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <vine:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice id="f96" decimals="INF" contextRef="c25" unitRef="usd">1.61</vine:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
  <us-gaap:InterestExpense id="f97" xsi:nil="true" contextRef="c31" unitRef="usd1"/>
  <us-gaap:SettlementLiabilitiesCurrent id="f98" decimals="0" contextRef="c13" unitRef="usd1">585976.0</us-gaap:SettlementLiabilitiesCurrent>
  <us-gaap:StockholdersEquity id="f99" decimals="0" contextRef="c21" unitRef="usd1">10.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f100" decimals="0" contextRef="c35" unitRef="usd1">749992.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:InterestExpense id="f101" xsi:nil="true" contextRef="c1" unitRef="usd1"/>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="f102" decimals="0" contextRef="c3" unitRef="usd1">2685.0</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f103" decimals="0" contextRef="c1" unitRef="usd1">4784535.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="f104" decimals="0" contextRef="c1" unitRef="usd1">-8564077.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:Revenues id="f105" decimals="0" contextRef="c36" unitRef="usd1">744532.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquity id="f106" decimals="0" contextRef="c37" unitRef="usd1">-28990067.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f107" xsi:nil="true" contextRef="c38" unitRef="usd1"/>
  <us-gaap:CostOfRevenue id="f108" decimals="0" contextRef="c31" unitRef="usd1">889844.0</us-gaap:CostOfRevenue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="f109" decimals="0" contextRef="c5" unitRef="usd1">1132517.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:PreferredStockDividendRatePercentage id="f110" decimals="INF" contextRef="c12" unitRef="pure">0.12</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:StockholdersEquity id="f111" xsi:nil="true" contextRef="c39" unitRef="usd1"/>
  <vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued id="f112" xsi:nil="true" contextRef="c40" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f113" decimals="0" contextRef="c41" unitRef="usd1">25457806.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="f114" decimals="INF" contextRef="c42" unitRef="shares">17017558.0</us-gaap:SharesOutstanding>
  <vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued id="f115" xsi:nil="true" contextRef="c43" unitRef="usd1"/>
  <us-gaap:Revenues id="f116" decimals="0" contextRef="c44" unitRef="usd1">198335.0</us-gaap:Revenues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f117" decimals="INF" contextRef="c45" unitRef="shares">100000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <dei:EntityAddressCityOrTown id="f118" contextRef="c5">Charlotte</dei:EntityAddressCityOrTown>
  <us-gaap:PreferredStockDividendRatePercentage id="f119" decimals="INF" contextRef="c46" unitRef="pure">0.5</us-gaap:PreferredStockDividendRatePercentage>
  <vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued id="f120" xsi:nil="true" contextRef="c47" unitRef="usd1"/>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f121" decimals="INF" contextRef="c1" unitRef="shares">15085911.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ProvisionForDoubtfulAccounts id="f122" decimals="0" contextRef="c1" unitRef="usd1">37733.0</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited id="f123" decimals="INF" contextRef="c32" unitRef="shares">500000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
  <us-gaap:NetIncomeLoss id="f124" decimals="0" contextRef="c48" unitRef="usd1">-2129660.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f125" xsi:nil="true" contextRef="c40" unitRef="usd1"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f126" xsi:nil="true" contextRef="c43" unitRef="usd1"/>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther id="f127" decimals="0" contextRef="c1" unitRef="usd1">74272.0</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <us-gaap:ConcentrationRiskPercentage1 id="f128" decimals="INF" contextRef="c49" unitRef="pure">0.878</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="f129" decimals="INF" contextRef="c50" unitRef="shares">25000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <dei:EntityAddressStateOrProvince id="f130" contextRef="c5">NC</dei:EntityAddressStateOrProvince>
  <us-gaap:StockholdersEquityOther id="f131" decimals="-6" contextRef="c51" unitRef="usd1">4000000.0</us-gaap:StockholdersEquityOther>
  <us-gaap:PreferredStockDividendRatePercentage id="f132" decimals="INF" contextRef="c52" unitRef="pure">0.12</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f133" xsi:nil="true" contextRef="c47" unitRef="usd1"/>
  <vine:StockDividends id="f134" decimals="0" contextRef="c3" unitRef="usd1">148000.0</vine:StockDividends>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="f135" decimals="0" contextRef="c53" unitRef="usd1">2080335.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f136" xsi:nil="true" contextRef="c40" unitRef="usd1"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f137" decimals="INF" contextRef="c3" unitRef="usd">8.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f138" xsi:nil="true" contextRef="c43" unitRef="usd1"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares id="f139" decimals="INF" contextRef="c1" unitRef="shares">25000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <dei:EntityAddressPostalZipCode id="f140" contextRef="c5">28271</dei:EntityAddressPostalZipCode>
  <us-gaap:IncomeTaxPolicyTextBlock id="f141" contextRef="c5">&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zMyorY0XDiI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zE7CcfhJlGf9"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes uncertain tax positions in
accordance with ASC 740 on the basis of evaluating whether it is more likely than not that the tax positions will be sustained upon examination
by tax authorities. For those tax positions that meet the more-likely-than not recognition threshold, the Company recognizes the largest
amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement. The Company recognizes interest and/or
penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of September 30, 2024 or
December 31, 2023, and as such, no interest or penalties were recorded to income tax expense. As of September 30, 2024 and December 31,
2023, the Company has no unrecognized tax benefits. There are no unrecognized tax benefits included on the balance sheet that would, if
recognized, impact the effective tax rate. The Company does not anticipate there will be a significant change in unrecognized tax benefits
within the next 12 months.&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
  <vine:PreferredStockDividendRatePercentage2 id="f142" decimals="INF" contextRef="c10" unitRef="pure">0.24</vine:PreferredStockDividendRatePercentage2>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f143" xsi:nil="true" contextRef="c47" unitRef="usd1"/>
  <us-gaap:CostOfRevenue id="f144" decimals="0" contextRef="c1" unitRef="usd1">3631491.0</us-gaap:CostOfRevenue>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f145" decimals="INF" contextRef="c3" unitRef="usd">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f146" xsi:nil="true" contextRef="c54" unitRef="usd1"/>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="f147" decimals="0" contextRef="c5" unitRef="usd1">106133.0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="f148" decimals="0" contextRef="c55" unitRef="usd1">805017.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="f149" decimals="0" contextRef="c5" unitRef="usd1">131353.0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:NetIncomeLoss id="f150" xsi:nil="true" contextRef="c40" unitRef="usd1"/>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f151" decimals="INF" contextRef="c13" unitRef="usd">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <vine:PerSharePercentage id="f152" decimals="INF" contextRef="c5" unitRef="pure">2.0</vine:PerSharePercentage>
  <us-gaap:NetIncomeLoss id="f153" xsi:nil="true" contextRef="c43" unitRef="usd1"/>
  <us-gaap:NetIncomeLoss id="f154" xsi:nil="true" contextRef="c32" unitRef="usd1"/>
  <us-gaap:GrossProfit id="f155" decimals="0" contextRef="c10" unitRef="usd1">152646.0</us-gaap:GrossProfit>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="f156" decimals="0" contextRef="c5" unitRef="usd1">-214272.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:NetIncomeLoss id="f157" xsi:nil="true" contextRef="c56" unitRef="usd1"/>
  <us-gaap:SharesOutstanding id="f158" decimals="INF" contextRef="c57" unitRef="shares">9135.0</us-gaap:SharesOutstanding>
  <us-gaap:ConcentrationRiskPercentage1 id="f159" decimals="INF" contextRef="c58" unitRef="pure">0.168</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommonStockSharesAuthorized id="f160" decimals="INF" contextRef="c13" unitRef="shares">100000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f161" decimals="0" contextRef="c30" unitRef="usd1">8.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="f162" decimals="0" contextRef="c13" unitRef="usd1">3407.0</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:StockholdersEquity id="f163" xsi:nil="true" contextRef="c59" unitRef="usd1"/>
  <vine:StockDividends id="f164" decimals="0" contextRef="c13" unitRef="usd1">41867.0</vine:StockDividends>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f165" decimals="INF" contextRef="c60" unitRef="shares">0.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:PreferredStockSharesAuthorized id="f166" decimals="INF" contextRef="c3" unitRef="shares">25000000.0</us-gaap:PreferredStockSharesAuthorized>
  <vine:ClosingPriceOfCommonStockAsExecutionAndDelivery id="f167" decimals="INF" contextRef="c5" unitRef="usd">0.47</vine:ClosingPriceOfCommonStockAsExecutionAndDelivery>
  <us-gaap:StockholdersEquity id="f168" xsi:nil="true" contextRef="c61" unitRef="usd1"/>
  <us-gaap:CostOfRevenue id="f169" decimals="0" contextRef="c5" unitRef="usd1">240539.0</us-gaap:CostOfRevenue>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f170" xsi:nil="true" contextRef="c62" unitRef="usd1"/>
  <us-gaap:PreferredStockSharesAuthorized id="f171" decimals="INF" contextRef="c13" unitRef="shares">25000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f172" decimals="INF" contextRef="c63" unitRef="shares">8000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f173" xsi:nil="true" contextRef="c64" unitRef="usd1"/>
  <us-gaap:InterestExpense id="f174" decimals="0" contextRef="c10" unitRef="usd1">6322.0</us-gaap:InterestExpense>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="f175" decimals="0" contextRef="c31" unitRef="usd1">15600.0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:StockholdersEquity id="f176" decimals="0" contextRef="c65" unitRef="usd1">-24398239.0</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f177" decimals="INF" contextRef="c66" unitRef="shares">105346.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f178" xsi:nil="true" contextRef="c67" unitRef="usd1"/>
  <us-gaap:Revenues id="f179" decimals="0" contextRef="c68" unitRef="usd1">394576.0</us-gaap:Revenues>
  <vine:StockIssuedDuringPeriodSharesRightsOfferingCommonStockAndWarrantsIssuedinShares id="f180" decimals="INF" contextRef="c32" unitRef="shares">3143969.0</vine:StockIssuedDuringPeriodSharesRightsOfferingCommonStockAndWarrantsIssuedinShares>
  <us-gaap:DividendsPreferredStockStock id="f181" decimals="0" contextRef="c5" unitRef="usd1">148000.0</us-gaap:DividendsPreferredStockStock>
  <us-gaap:NetIncomeLoss id="f182" xsi:nil="true" contextRef="c62" unitRef="usd1"/>
  <us-gaap:AccruedLiabilitiesCurrent id="f183" decimals="0" contextRef="c3" unitRef="usd1">1125942.0</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f184" decimals="INF" contextRef="c" unitRef="shares">744000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f185" decimals="0" contextRef="c32" unitRef="usd1">-500.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
  <us-gaap:DividendsPreferredStock id="f186" decimals="0" contextRef="c69" unitRef="usd1">30000.0</us-gaap:DividendsPreferredStock>
  <vine:PromissoryNoteInterestRatePerAnnum id="f187" decimals="INF" contextRef="c70" unitRef="pure">0.06</vine:PromissoryNoteInterestRatePerAnnum>
  <us-gaap:NetIncomeLoss id="f188" xsi:nil="true" contextRef="c64" unitRef="usd1"/>
  <us-gaap:ShareBasedCompensation id="f189" decimals="0" contextRef="c10" unitRef="usd1">1626.0</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f190" decimals="INF" contextRef="c71" unitRef="shares">0.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:InvestmentTextBlock id="f191" contextRef="c5">&lt;p id="xdx_807_eus-gaap--InvestmentTextBlock_zdin7MfqJqi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_825_zWtDnvn8Cfn3"&gt;5. INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Plan of Merger in December
2023 (as described in Note 1), the Company made a $&lt;span id="xdx_906_eus-gaap--EquityMethodInvestments_iI_c20231231_zEI9bezDdLW5"&gt;500,000&lt;/span&gt; investment for &lt;span id="xdx_90B_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231_zTJd0fEQtRgi"&gt;50,000&lt;/span&gt; shares of Notes Live, Inc. The investment was initially
measured at cost. The Company noted no impairment or fair value change as of September 30, 2024.&lt;/p&gt;

</us-gaap:InvestmentTextBlock>
  <us-gaap:NetIncomeLoss id="f192" xsi:nil="true" contextRef="c72" unitRef="usd1"/>
  <us-gaap:CommonStockSharesAuthorized id="f193" decimals="INF" contextRef="c3" unitRef="shares">100000000.0</us-gaap:CommonStockSharesAuthorized>
  <vine:ScheduleOfSeriesAStockIssuanceActivityTableTextBlock id="f194" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfSeriesAStockIssuanceActivityTableTextBlock_z3lUrqegpQO" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Issuance activity of Series A Stock (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20240701__20240930_zIx46TRIyBC" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20230701__20230930_zGsshOZB3gWc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49F_20240101__20240930_zBPolax1dGQg" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20230101__20230930_zCFSlFohRSX4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1bV0vnCQM77" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;Series A preferred stock shares issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0834"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFuCJUjF5xEf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net proceeds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;750,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;750,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</vine:ScheduleOfSeriesAStockIssuanceActivityTableTextBlock>
  <us-gaap:NetIncomeLoss id="f195" xsi:nil="true" contextRef="c73" unitRef="usd1"/>
  <us-gaap:ConcentrationRiskPercentage1 id="f196" decimals="INF" contextRef="c74" unitRef="pure">0.751</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f197" xsi:nil="true" contextRef="c75" unitRef="usd1"/>
  <us-gaap:GrossProfit id="f198" decimals="0" contextRef="c31" unitRef="usd1">-41885.0</us-gaap:GrossProfit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f199" decimals="INF" contextRef="c76" unitRef="shares">598404.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f200" decimals="INF" contextRef="c10" unitRef="shares">15976227.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:StockholdersEquity id="f201" xsi:nil="true" contextRef="c77" unitRef="usd1"/>
  <vine:StockIssuedAndOutstanding id="f202" decimals="INF" contextRef="c78" unitRef="pure">0.5</vine:StockIssuedAndOutstanding>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="f203" contextRef="c5">&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zrNbfe5cOAE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zlq0M7aNkHd6"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company measures equity-based compensation cost
at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which
is generally the vesting period. The Company recognizes any forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company measures equity-based compensation when
the service inception date precedes the grant date based on the fair value of the award as an accrual of equity-based compensation and
adjusts the cost to fair value at each reporting date prior to the grant date. In the period in which the grant occurs, the cumulative
compensation cost is adjusted to the fair value at the date of the grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;See Note 9 for further discussion of equity-based
compensation incurred in 2024 and 2023.&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:CommonStockConvertibleConversionPriceDecrease id="f204" decimals="INF" contextRef="c5" unitRef="usd">0.05</us-gaap:CommonStockConvertibleConversionPriceDecrease>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f205" xsi:nil="true" contextRef="c79" unitRef="usd1"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f206" xsi:nil="true" contextRef="c80" unitRef="usd1"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f207" xsi:nil="true" contextRef="c48" unitRef="usd1"/>
  <us-gaap:SharesOutstanding id="f208" decimals="INF" contextRef="c81" unitRef="shares">12732257.0</us-gaap:SharesOutstanding>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="f209" decimals="0" contextRef="c5" unitRef="usd1">647600.0</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:AccruedProfessionalFeesCurrent id="f210" decimals="0" contextRef="c3" unitRef="usd1">47924.0</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:DividendsPreferredStockStock id="f211" decimals="0" contextRef="c82" unitRef="usd1">41867.0</us-gaap:DividendsPreferredStockStock>
  <us-gaap:DividendsPreferredStock id="f212" xsi:nil="true" contextRef="c30" unitRef="usd1"/>
  <us-gaap:DividendsPreferredStock id="f213" xsi:nil="true" contextRef="c79" unitRef="usd1"/>
  <us-gaap:ProceedsFromConvertibleDebt id="f214" decimals="0" contextRef="c5" unitRef="usd1">300000.0</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="f215" decimals="0" contextRef="c1" unitRef="usd1">-1220389.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:DividendsPreferredStock id="f216" xsi:nil="true" contextRef="c80" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f217" decimals="0" contextRef="c57" unitRef="usd1">9.0</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock id="f218" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zQgvDPfVjg2d" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Restricted stock activity and vendor stock award activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_4B3_us-gaap--AwardTypeAxis_us-gaap--RestrictedStockMember_zUZbgVtJTLzg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;br/&gt; Shares of Restricted Stock&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43E_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_zWNaT4m7OJu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_pip0_dtY_c20231231__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgmQAwR6r3u5"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_zsXixXCfcyb4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_434_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_zwcFgGm3vpz" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested or released&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_zfVLW8qUFaph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0895"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_439_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_zYS71cw41yX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0897"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5tIcPErTiii"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Vendor Stock Awards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Vendor stock award activity subject to revenue-related
performance objectives during the nine months ended September 30, 2024 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_4BA_us-gaap--AwardTypeAxis_custom--VendorStockAwardsMember_zJBZKQZCiIVb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of Shares of Vendor Stock Awards&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Vesting&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_433_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_zmNBusOJzpyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;1,030,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_pip0_dtY_c20231231__20231231__us-gaap--AwardTypeAxis__custom--VendorStockAwardsMember_zZxciQUC68Dd"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43A_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_zejr6RWPBVil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_432_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_zgO5PgI7gPC" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested or released&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_435_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_zAI9gyCbxOrb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_431_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_zLVBKSdZh40j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,030,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_pip0_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__custom--VendorStockAwardsMember_zEXwQxqNPFX1"&gt;0.46&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock>
  <vine:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice id="f219" decimals="INF" contextRef="c" unitRef="usd">0.44</vine:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice>
  <us-gaap:DividendsPreferredStock id="f220" xsi:nil="true" contextRef="c35" unitRef="usd1"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f221" decimals="0" contextRef="c31" unitRef="usd1">750000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="f222" decimals="0" contextRef="c1" unitRef="usd1">3365014.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f223" xsi:nil="true" contextRef="c30" unitRef="usd1"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f224" xsi:nil="true" contextRef="c79" unitRef="usd1"/>
  <us-gaap:AdditionalPaidInCapital id="f225" decimals="0" contextRef="c3" unitRef="usd1">26572493.0</us-gaap:AdditionalPaidInCapital>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f226" xsi:nil="true" contextRef="c80" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f227" decimals="0" contextRef="c23" unitRef="usd1">1075551.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f228" decimals="0" contextRef="c83" unitRef="usd1">90324.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <dei:CityAreaCode id="f229" contextRef="c5">(855)</dei:CityAreaCode>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f230" xsi:nil="true" contextRef="c48" unitRef="usd1"/>
  <us-gaap:NatureOfOperations id="f231" contextRef="c5">&lt;p id="xdx_847_eus-gaap--NatureOfOperations_zPfzuu03vM67" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_ztOuWmJObHt5"&gt;Nature of Business&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fresh Vine Wine, Inc. (the Company,
our, we), a Nevada corporation, is a premium wine brand built to complement consumers healthy and active
lifestyles. The Company provides a competitively priced premium product that is blended to deliver several important benefits, such as
low-cal, low-sugar, low-carb. The Companys wines are also gluten-free and keto and vegan friendly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Companys revenue is comprised primarily
of wholesale and direct to consumer (DTC) sales, and representation and distribution services. Wholesale revenue is generated through
sales to distributors located in states throughout the United States of America. DTC revenue is generated from individuals purchasing
wine directly from the Company through club membership and the Companys website.&lt;/p&gt;

</us-gaap:NatureOfOperations>
  <us-gaap:ConcentrationRiskPercentage1 id="f232" decimals="INF" contextRef="c84" unitRef="pure">0.877</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f233" decimals="INF" contextRef="c26" unitRef="shares">8000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f234" xsi:nil="true" contextRef="c30" unitRef="usd1"/>
  <us-gaap:AccruedLiabilitiesCurrent id="f235" decimals="0" contextRef="c13" unitRef="usd1">810723.0</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OperatingIncomeLoss id="f236" decimals="0" contextRef="c31" unitRef="usd1">-2129690.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:AccruedProfessionalFeesCurrent id="f237" decimals="0" contextRef="c13" unitRef="usd1">125704.0</us-gaap:AccruedProfessionalFeesCurrent>
  <vine:PricePerShareOfRedemptionPercentage id="f238" decimals="INF" contextRef="c55" unitRef="pure">1.5</vine:PricePerShareOfRedemptionPercentage>
  <us-gaap:DividendsPreferredStock id="f239" decimals="0" contextRef="c28" unitRef="usd1">30000.0</us-gaap:DividendsPreferredStock>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f240" xsi:nil="true" contextRef="c79" unitRef="usd1"/>
  <dei:Security12bTitle id="f241" contextRef="c5">Common stock, $0.001 par     value</dei:Security12bTitle>
  <us-gaap:OtherNotesPayableCurrent id="f242" decimals="0" contextRef="c3" unitRef="usd1">27500.0</us-gaap:OtherNotesPayableCurrent>
  <us-gaap:ShareBasedCompensation id="f243" decimals="0" contextRef="c31" unitRef="usd1">946415.0</us-gaap:ShareBasedCompensation>
  <vine:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice id="f244" decimals="INF" contextRef="c27" unitRef="usd">1.4</vine:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f245" xsi:nil="true" contextRef="c48" unitRef="usd1"/>
  <us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable id="f246" decimals="0" contextRef="c1" unitRef="usd1">804907.0</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
  <us-gaap:CommonStockConvertibleConversionPriceIncrease id="f247" decimals="INF" contextRef="c5" unitRef="usd">0.45</us-gaap:CommonStockConvertibleConversionPriceIncrease>
  <us-gaap:NetIncomeLoss id="f248" decimals="0" contextRef="c69" unitRef="usd1">-1212315.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f249" xsi:nil="true" contextRef="c31" unitRef="usd1"/>
  <us-gaap:LiabilitiesCurrent id="f250" decimals="0" contextRef="c13" unitRef="usd1">2218776.0</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f251" decimals="INF" contextRef="c13" unitRef="usd">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:NetIncomeLoss id="f252" xsi:nil="true" contextRef="c30" unitRef="usd1"/>
  <us-gaap:GrossProfit id="f253" decimals="0" contextRef="c5" unitRef="usd1">-2278.0</us-gaap:GrossProfit>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f254" decimals="INF" contextRef="c31" unitRef="shares">15976227.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:NetIncomeLoss id="f255" xsi:nil="true" contextRef="c79" unitRef="usd1"/>
  <us-gaap:Revenues id="f256" decimals="0" contextRef="c10" unitRef="usd1">63209.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquity id="f257" decimals="0" contextRef="c85" unitRef="usd1">24595025.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f258" xsi:nil="true" contextRef="c80" unitRef="usd1"/>
  <us-gaap:NetIncomeLoss id="f259" decimals="0" contextRef="c86" unitRef="usd1">-315290.0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="f260" xsi:nil="true" contextRef="c35" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f261" xsi:nil="true" contextRef="c87" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f262" decimals="0" contextRef="c81" unitRef="usd1">12732.0</us-gaap:StockholdersEquity>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="f263" decimals="0" contextRef="c1" unitRef="usd1">-34492.0</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ConcentrationRiskPercentage1 id="f264" decimals="INF" contextRef="c88" unitRef="pure">0.122</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockDividendRatePercentage id="f265" decimals="INF" contextRef="c31" unitRef="pure">0.12</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:StockholdersEquity id="f266" decimals="0" contextRef="c89" unitRef="usd1">15976.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f267" xsi:nil="true" contextRef="c90" unitRef="usd1"/>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f268" decimals="INF" contextRef="c3" unitRef="usd">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f269" xsi:nil="true" contextRef="c91" unitRef="usd1"/>
  <us-gaap:DividendsPreferredStock id="f270" decimals="0" contextRef="c31" unitRef="usd1">15600.0</us-gaap:DividendsPreferredStock>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f271" xsi:nil="true" contextRef="c92" unitRef="usd1"/>
  <us-gaap:InventoryLIFOReserveEffectOnIncomeNet id="f272" decimals="0" contextRef="c10" unitRef="usd1">-154483.0</us-gaap:InventoryLIFOReserveEffectOnIncomeNet>
  <us-gaap:EarningsPerShareBasic id="f273" decimals="INF" contextRef="c10" unitRef="usd">-0.02</us-gaap:EarningsPerShareBasic>
  <us-gaap:SharesOutstanding id="f274" decimals="INF" contextRef="c93" unitRef="shares">15976227.0</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f275" xsi:nil="true" contextRef="c69" unitRef="usd1"/>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f276" decimals="0" contextRef="c10" unitRef="usd1">459988.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:DividendsPreferredStock id="f277" xsi:nil="true" contextRef="c91" unitRef="usd1"/>
  <us-gaap:IncreaseDecreaseInInventories id="f278" decimals="0" contextRef="c5" unitRef="usd1">105047.0</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="f279" decimals="0" contextRef="c3" unitRef="usd1">93778.0</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdvertisingCostsPolicyTextBlock id="f280" contextRef="c5">&lt;p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_z4ecroRc39R6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zK9ulM3gKjpc"&gt;Advertising&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the costs of advertising as incurred.
Advertising expenses were approximately $&lt;span id="xdx_90C_eus-gaap--AdvertisingExpense_c20240701__20240930_zfRkOpCu1OTa"&gt;7,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AdvertisingExpense_c20230701__20230930_zgsdtDwJsF55"&gt;258,000&lt;/span&gt; for the three months ended September 30, 2024 and 2023, respectively and was
approximately $&lt;span id="xdx_903_eus-gaap--AdvertisingExpense_c20240101__20240930_zUjoYyCMqfPd"&gt;334,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AdvertisingExpense_pin6_c20230101__20230930_zP00tGyPMC4g"&gt;1.4&lt;/span&gt; million for the nine months ended September 30, 2024 and 2023, respectively.&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
  <us-gaap:PreferredStockConvertibleConversionPrice id="f281" decimals="INF" contextRef="c94" unitRef="usd">0.45</us-gaap:PreferredStockConvertibleConversionPrice>
  <vine:StockIssuedAndOutstanding id="f282" decimals="INF" contextRef="c55" unitRef="pure">0.75</vine:StockIssuedAndOutstanding>
  <us-gaap:DividendsPreferredStock id="f283" xsi:nil="true" contextRef="c7" unitRef="usd1"/>
  <us-gaap:DividendsPreferredStock id="f284" xsi:nil="true" contextRef="c92" unitRef="usd1"/>
  <us-gaap:DividendsPreferredStock id="f285" xsi:nil="true" contextRef="c83" unitRef="usd1"/>
  <us-gaap:InterestExpense id="f286" decimals="0" contextRef="c5" unitRef="usd1">6322.0</us-gaap:InterestExpense>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f287" decimals="INF" contextRef="c95" unitRef="usd">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f288" xsi:nil="true" contextRef="c91" unitRef="usd1"/>
  <us-gaap:ConcentrationRiskPercentage1 id="f289" decimals="INF" contextRef="c96" unitRef="pure">0.832</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f290" xsi:nil="true" contextRef="c7" unitRef="usd1"/>
  <us-gaap:ShareBasedCompensation id="f291" decimals="0" contextRef="c5" unitRef="usd1">4878.0</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f292" xsi:nil="true" contextRef="c69" unitRef="usd1"/>
  <us-gaap:NetIncomeLoss id="f293" decimals="0" contextRef="c28" unitRef="usd1">-1212315.0</us-gaap:NetIncomeLoss>
  <vine:PreferredStockSharesDesignates id="f294" decimals="INF" contextRef="c97" unitRef="shares">50000.0</vine:PreferredStockSharesDesignates>
  <us-gaap:NetIncomeLoss id="f295" xsi:nil="true" contextRef="c91" unitRef="usd1"/>
  <us-gaap:NetIncomeLoss id="f296" xsi:nil="true" contextRef="c7" unitRef="usd1"/>
  <us-gaap:GrossProfit id="f297" decimals="0" contextRef="c1" unitRef="usd1">-2044777.0</us-gaap:GrossProfit>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f298" decimals="INF" contextRef="c5" unitRef="shares">15976227.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:NetIncomeLoss id="f299" xsi:nil="true" contextRef="c92" unitRef="usd1"/>
  <us-gaap:Revenues id="f300" decimals="0" contextRef="c31" unitRef="usd1">847959.0</us-gaap:Revenues>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="f301" decimals="0" contextRef="c13" unitRef="usd1">27059.0</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:PreferredStockSharesOutstanding id="f302" decimals="INF" contextRef="c98" unitRef="shares">10000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="f303" decimals="0" contextRef="c63" unitRef="usd1">750000.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:NetIncomeLoss id="f304" xsi:nil="true" contextRef="c83" unitRef="usd1"/>
  <us-gaap:OtherLiabilitiesCurrent id="f305" decimals="0" contextRef="c3" unitRef="usd1">309333.0</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f306" xsi:nil="true" contextRef="c99" unitRef="usd1"/>
  <us-gaap:PreferredStockSharesOutstanding id="f307" decimals="INF" contextRef="c100" unitRef="shares">10000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:StockholdersEquityOther id="f308" decimals="0" contextRef="c101" unitRef="usd1">2000000.0</us-gaap:StockholdersEquityOther>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f309" xsi:nil="true" contextRef="c102" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f310" decimals="0" contextRef="c103" unitRef="usd1">21420732.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f311" xsi:nil="true" contextRef="c104" unitRef="usd1"/>
  <us-gaap:OtherNonoperatingIncomeExpense id="f312" decimals="0" contextRef="c31" unitRef="usd1">30.0</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ConcentrationRiskPercentage1 id="f313" decimals="INF" contextRef="c105" unitRef="pure">0.249</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:DividendsPreferredStock id="f314" xsi:nil="true" contextRef="c99" unitRef="usd1"/>
  <dei:EntityCurrentReportingStatus id="f315" contextRef="c5">Yes</dei:EntityCurrentReportingStatus>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f316" decimals="INF" contextRef="c1" unitRef="shares">15085911.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:DividendsPreferredStock id="f317" xsi:nil="true" contextRef="c106" unitRef="usd1"/>
  <us-gaap:EarningsPerShareBasic id="f318" decimals="INF" contextRef="c31" unitRef="usd">-0.13</us-gaap:EarningsPerShareBasic>
  <us-gaap:StockholdersEquity id="f319" decimals="0" contextRef="c93" unitRef="usd1">15976.0</us-gaap:StockholdersEquity>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f320" decimals="0" contextRef="c31" unitRef="usd1">1141390.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:DividendsPreferredStock id="f321" xsi:nil="true" contextRef="c102" unitRef="usd1"/>
  <us-gaap:DividendsPreferredStock id="f322" xsi:nil="true" contextRef="c107" unitRef="usd1"/>
  <us-gaap:InventoryNet id="f323" decimals="0" contextRef="c13" unitRef="usd1">337873.0</us-gaap:InventoryNet>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="f324" decimals="0" contextRef="c5" unitRef="usd1">6322.0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:InventoryFinishedGoods id="f325" decimals="0" contextRef="c13" unitRef="usd1">338000.0</us-gaap:InventoryFinishedGoods>
  <us-gaap:PrepaidInsurance id="f326" decimals="0" contextRef="c13" unitRef="usd1">33072.0</us-gaap:PrepaidInsurance>
  <vine:PurchaseOfShareValueOfGrossProceeds id="f327" decimals="0" contextRef="c108" unitRef="usd1">1000000.0</vine:PurchaseOfShareValueOfGrossProceeds>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f328" decimals="INF" contextRef="c109" unitRef="usd">100.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f329" xsi:nil="true" contextRef="c99" unitRef="usd1"/>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="f330" decimals="0" contextRef="c10" unitRef="usd1">131353.0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <vine:ProceedsFromSecuredConvertiblePromissoryNotes id="f331" decimals="0" contextRef="c5" unitRef="usd1">300000.0</vine:ProceedsFromSecuredConvertiblePromissoryNotes>
  <vine:PromissoryNoteInterestRatePerAnnumIncrease id="f332" decimals="INF" contextRef="c70" unitRef="pure">0.12</vine:PromissoryNoteInterestRatePerAnnumIncrease>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f333" decimals="INF" contextRef="c106" unitRef="shares">8195.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <vine:NetExpenseRelatingToAgreements id="f334" decimals="0" contextRef="c110" unitRef="usd1">0.0</vine:NetExpenseRelatingToAgreements>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f335" xsi:nil="true" contextRef="c106" unitRef="usd1"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f336" decimals="INF" contextRef="c3" unitRef="shares">69892.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <dei:EntityExTransitionPeriod id="f337" contextRef="c5">false</dei:EntityExTransitionPeriod>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f338" xsi:nil="true" contextRef="c102" unitRef="usd1"/>
  <us-gaap:EarningsPerShareTextBlock id="f339" contextRef="c5">&lt;p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zdtHZjGuTbQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_828_ztw5ZhzOogO4"&gt;2. LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is determined by dividing
net loss attributable to common shareholders by the weighted-average shares outstanding during the period. Diluted EPS reflects potential
dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased
by the numbers of additional common shares that would have been outstanding if all potential common shares had been issued and were dilutive.
However, potentially dilutive securities are excluded from the computation of diluted EPS to the extent that their effect is anti-dilutive.
The following table shows the components of diluted shares for the periods ending:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNUsBae6B2A4" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Components of diluted shares (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20240701__20240930_zRIrlDOXUOuj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20230701__20230930_z3rqsn7KySg6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240101__20240930_zi6oKd4Ur0k" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_490_20230101__20230930_ziYdGUR8IVl1" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_z1HLh8A6ol0d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(315,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(2,129,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(2,407,174&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(8,562,781&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PreferredStockDividendsIncomeStatementImpact_z9SRkPQAFTgd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in"&gt;Less: dividends on Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;106,133&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z2Laz0AXoFL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(365,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,145,260&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,513,307&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(8,578,381&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zIYPEMQYqyvd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 0.25in"&gt;Basic  weighted shares outstanding&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,085,911&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zWhlkw2sMqO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in"&gt;Dilutive effect from shares authorized&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0677"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0679"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zKsMZFHv59Cd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Diluted  weighted shares outstanding&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,085,911&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EarningsPerShareBasic_z9sweBeN5TT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Basic loss per share&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.57&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_zDknef3e0S2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Diluted loss per share&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.57&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zLm6339mEN31" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2024 and 2023, &lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_znr7dqSeQaXk"&gt;17,502,861&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_z7DSKcNuMhBk"&gt;5,905,528&lt;/span&gt;
shares have been excluded from the calculation of diluted weighted average shares outstanding as the inclusion of these shares would have
an anti-dilutive effect.&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="f340" decimals="INF" contextRef="c5" unitRef="shares">9135.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f341" xsi:nil="true" contextRef="c104" unitRef="usd1"/>
  <vine:FairValueOfWarrantsRecorded id="f342" decimals="0" contextRef="c3" unitRef="usd1">131353.0</vine:FairValueOfWarrantsRecorded>
  <vine:NetExpenseRelatingToAgreements id="f343" decimals="0" contextRef="c111" unitRef="usd1">329333.0</vine:NetExpenseRelatingToAgreements>
  <us-gaap:NetIncomeLoss id="f344" xsi:nil="true" contextRef="c99" unitRef="usd1"/>
  <us-gaap:CommonStockValue id="f345" decimals="0" contextRef="c13" unitRef="usd1">15976.0</us-gaap:CommonStockValue>
  <us-gaap:Revenues id="f346" decimals="0" contextRef="c112" unitRef="usd1">7766.0</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss id="f347" xsi:nil="true" contextRef="c106" unitRef="usd1"/>
  <us-gaap:LiabilitiesCurrent id="f348" decimals="0" contextRef="c3" unitRef="usd1">3383342.0</us-gaap:LiabilitiesCurrent>
  <us-gaap:DisaggregationOfRevenueTableTextBlock id="f349" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--DisaggregationOfRevenueTableTextBlock_zN7gai0phEHi" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Percentages of total revenue disaggregated by sales channels (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three months ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine months ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%"&gt;Wholesale&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zHYqeVqRPaC2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;12.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zgAFI1it8t6h" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;87.8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_ze5cXGNEq8N6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;16.8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zJQepgzTwEda" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;75.1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Direct to consumer&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJXLSVk3nMn7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;87.7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpKaDWLgVk59" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z0DB2aexn1dj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwvplope6jV" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;24.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zKqmk03Ur8s8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zAdgsp416ha4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zimSnritT8pk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zjyhoOLYdSNd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
  <us-gaap:PreferredStockValue id="f350" decimals="0" contextRef="c98" unitRef="usd1">10.0</us-gaap:PreferredStockValue>
  <vine:GrossProceeds id="f351" decimals="0" contextRef="c5" unitRef="usd1">913500.0</vine:GrossProceeds>
  <us-gaap:NetIncomeLoss id="f352" xsi:nil="true" contextRef="c102" unitRef="usd1"/>
  <vine:OriginalIssueDiscountRecorded id="f353" decimals="0" contextRef="c3" unitRef="usd1">191353.0</vine:OriginalIssueDiscountRecorded>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f354" decimals="0" contextRef="c107" unitRef="usd1">714684.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss id="f355" xsi:nil="true" contextRef="c107" unitRef="usd1"/>
  <us-gaap:DividendsPreferredStock id="f356" xsi:nil="true" contextRef="c113" unitRef="usd1"/>
  <us-gaap:ConcentrationRiskPercentage1 id="f357" decimals="INF" contextRef="c114" unitRef="pure">1.0</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OtherAssetsDisclosureTextBlock id="f358" contextRef="c5">&lt;p id="xdx_80D_eus-gaap--OtherAssetsDisclosureTextBlock_zdgrSYWbT2x8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_820_zN3I6cFM5jUl"&gt;4. PREPAID EXPENSES&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses consist of the following at:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_zfoVScwcfzvh" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid expenses (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20240930_zyGvo9yHgbyh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_490_20231231_zwKEr4Qn1BI8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December31,&lt;br/&gt; 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherPrepaidExpenseCurrent_iI_zLoVj2UokW11" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify"&gt;Prepaid marketing expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;63,750&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;9,871&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_zoi6RqGlT7Pe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,839&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_z0ISeRmotEz2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;81,589&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,943&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zyacev5cQvXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 5pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
  <us-gaap:DividendsPreferredStock id="f359" decimals="0" contextRef="c48" unitRef="usd1">15600.0</us-gaap:DividendsPreferredStock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="f360" contextRef="c5">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zZ5koyrm6wWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zKVyx2kOTk69"&gt;Restricted Cash&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Included in the cash balance is a balance of approximately
$&lt;span id="xdx_906_eus-gaap--RestrictedCashCurrent_iI_dxL_c20240930_zl7nBjhhLDvj" title="::XDX::50039"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0606"&gt;50,000&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--RestrictedCashCurrent_iI_c20231231_zEs72MdcA0O6"&gt;100,000&lt;/span&gt; as of September 30, 2024 and December 31, 2023, respectively, that the Companys operating bank has required
us to maintain as a security for collectability of automated clearing house transactions. These funds are held in a separate account and
are not available for disbursements.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:PreferredStockConvertibleConversionPrice id="f361" decimals="INF" contextRef="c89" unitRef="usd">0.1</us-gaap:PreferredStockConvertibleConversionPrice>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f362" decimals="INF" contextRef="c55" unitRef="shares">9135.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="f363" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeZ1yaPbxAWe" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock option activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240930_zCdsSkEgrWRc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;446,559&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_z6khs5NZxf2e"&gt;8.88&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pip0_dtY_c20231231__20231231_zpVXXBdadlx3"&gt;8.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240930_zCTlZsUwlHSd"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zXBDYcr8iHai"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240930_zUxSaHEjPFe4"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_z2hu4hgugFbk"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0919"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240930_znnEDe59cCCa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,666&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240930_zl0DU1mKi5b"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240930_zhhmxoSFW9El" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;444,893&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_zdeL324TGwZ1"&gt;8.91&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pip0_dtY_c20240101__20240930_zc0yE7EBiqlj"&gt;7.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240930_z4NeqoLinr0d" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;69,892&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240930_z7WdflQv2fL8"&gt;3.04&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pip0_dtY_c20240101__20240930_zbQh03MZKAB5"&gt;7.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:DividendsPreferredStock id="f364" xsi:nil="true" contextRef="c115" unitRef="usd1"/>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="f365" decimals="INF" contextRef="c72" unitRef="shares">1141332.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:AccruedLiabilitiesCurrent id="f366" decimals="0" contextRef="c116" unitRef="usd1">309000.0</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:DividendsPreferredStock id="f367" xsi:nil="true" contextRef="c117" unitRef="usd1"/>
  <us-gaap:Revenues id="f368" decimals="0" contextRef="c118" unitRef="usd1">39926.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquity id="f369" decimals="0" contextRef="c119" unitRef="usd1">-17830682.0</us-gaap:StockholdersEquity>
  <vine:PercentageOfGrossProceed id="f370" decimals="INF" contextRef="c5" unitRef="pure">0.08</vine:PercentageOfGrossProceed>
  <us-gaap:AccruedLiabilitiesCurrent id="f371" decimals="0" contextRef="c120" unitRef="usd1">309000.0</us-gaap:AccruedLiabilitiesCurrent>
  <dei:DocumentTransitionReport id="f372" contextRef="c5">false</dei:DocumentTransitionReport>
  <us-gaap:DividendsPreferredStock id="f373" xsi:nil="true" contextRef="c121" unitRef="usd1"/>
  <us-gaap:Assets id="f374" decimals="0" contextRef="c13" unitRef="usd1">1389257.0</us-gaap:Assets>
  <us-gaap:NetIncomeLoss id="f375" decimals="0" contextRef="c31" unitRef="usd1">-2129660.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="f376" decimals="0" contextRef="c122" unitRef="usd1">-15819858.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="f377" decimals="INF" contextRef="c123" unitRef="shares">10000.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f378" decimals="0" contextRef="c124" unitRef="usd1">25723204.0</us-gaap:StockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f379" decimals="INF" contextRef="c125" unitRef="usd">100.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <vine:ScheduleOfSeriesBStockIssuanceActivityTableTextBlock id="f380" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfSeriesBStockIssuanceActivityTableTextBlock_zSUCa9mpSEXc" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Issuance activity of Series B Stock (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240701__20240930_zPzsfdvsaAR" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20230701__20230930_zLPJjngoWH77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20240101__20240930_zzdeGNlKvrB4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20230101__20230930_zpwIjqJIEYRa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three months ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine months ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWzV4imQqCj3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;Series B preferred stock shares issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;9,135&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0867"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztcBn91r8Qhb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net proceeds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;805,017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0872"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</vine:ScheduleOfSeriesBStockIssuanceActivityTableTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f381" xsi:nil="true" contextRef="c113" unitRef="usd1"/>
  <us-gaap:SharesOutstanding id="f382" decimals="INF" contextRef="c126" unitRef="shares">10000.0</us-gaap:SharesOutstanding>
  <vine:WorkingCapital id="f383" decimals="0" contextRef="c3" unitRef="usd1">-2900000.0</vine:WorkingCapital>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="f384" decimals="INF" contextRef="c3" unitRef="usd">3.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:LegalMattersAndContingenciesTextBlock id="f385" contextRef="c5">&lt;p id="xdx_80A_eus-gaap--LegalMattersAndContingenciesTextBlock_zCpKjd4C7hUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_82F_zy07q7TL9d55"&gt;13. LEGAL PROCEEDINGS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Aptos; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Timothy Michaels&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 24, 2022, Timothy Michaels, the former
Chief Operating Officer of the Company, signed a Separation Agreement and Release (the Separation Agreement) in connection
with the termination of his employment with the Company, which occurred on February 7, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 27, 2022, Mr. Michaels filed a complaint against
the Company in the Fourth Judicial District Court, Hennepin County, Minnesota, alleging that the Company breached the February 24, 2022
Separation Agreement by including a restricted lock-up legend on shares of the Companys common stock issued to Mr.
Michaels pursuant to the Settlement Agreement. The complaint also included counts alleging breach of the implied covenant of good
faith and fair dealing, issuer liability under Minn. Stat. 336.8-401 for delay in removing or directing the Companys
transfer agent to remove the lock-up legend from the shares, conversion and civil theft.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company made a motion seeking dismissal of
the conversion and civil theft counts, which was granted by the Fourth Judicial District Court, Hennepin County, Minnesota on
October 31, 2022. On August 9, 2023, the Company moved for summary judgment on Mr. Michaels remaining claims. A jury trial
commenced on January 23, 2024. During trial, on January 24, 2024, the Company filed a motion for judgement in favor of the Company
as a matter of law, which was denied by the Court. On January 25, 2024, the jury in the lawsuit rendered a verdict against the
Company awarding damages to Mr. Michaels in the amount of $&lt;span id="xdx_907_eus-gaap--LossContingencyDamagesAwardedValue_pp2p0_c20240125__20240125__us-gaap--RelatedPartyTransactionAxis__custom--MrMichaelsMember_zAzRKauvDYB1"&gt;585,976.25&lt;/span&gt;, which is included in settlement payable in the accompanying
balance sheet. On February 22, 2024, the Company filed a renewed motion for post-verdict judgment in favor of the Company as a
matter of law. On February 26, 2024, the Judge in the lawsuit denied the renewed motion for post-verdict judgment. On March 25,
2024, Mr. Michaels filed a Notice and Application for Taxation of Costs and Disbursements. On March 26, 2024, the Company filed its
Notice of Appeal. On March 26, 2024, Mr. Michaels served a motion for Pre-verdict and Prejudgment Interest. On March 27, 2024, a
Notice of Entry of Judgment was filed and, on March 28, 2024, a Notice of Docketing of Judgment was entered. Mr. Michaels has
commenced garnishment proceedings against certain of the Companys bank accounts and other third parties in an attempt to
collect on the judgment and such proceedings remain pending.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:LegalMattersAndContingenciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f386" xsi:nil="true" contextRef="c115" unitRef="usd1"/>
  <us-gaap:NetIncomeLoss id="f387" decimals="0" contextRef="c1" unitRef="usd1">-8562781.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f388" decimals="0" contextRef="c35" unitRef="usd1">1041.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
  <vine:DebtInstrumentNetOfUnamortizedDiscountCurrent id="f389" decimals="0" contextRef="c3" unitRef="usd1">174969.0</vine:DebtInstrumentNetOfUnamortizedDiscountCurrent>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f390" decimals="0" contextRef="c56" unitRef="usd1">257172.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <vine:AccruedDividends id="f391" decimals="0" contextRef="c5" unitRef="usd1">106133.0</vine:AccruedDividends>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f392" xsi:nil="true" contextRef="c117" unitRef="usd1"/>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f393" decimals="0" contextRef="c13" unitRef="usd1">-26476760.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:EarningsPerShareBasic id="f394" decimals="INF" contextRef="c5" unitRef="usd">-0.15</us-gaap:EarningsPerShareBasic>
  <us-gaap:StockholdersEquity id="f395" decimals="0" contextRef="c127" unitRef="usd1">26439514.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f396" xsi:nil="true" contextRef="c86" unitRef="usd1"/>
  <us-gaap:AdditionalPaidInCapital id="f397" decimals="0" contextRef="c13" unitRef="usd1">25631255.0</us-gaap:AdditionalPaidInCapital>
  <us-gaap:SharesOutstanding id="f398" decimals="INF" contextRef="c128" unitRef="shares">10000.0</us-gaap:SharesOutstanding>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="f399" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNUsBae6B2A4" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Components of diluted shares (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20240701__20240930_zRIrlDOXUOuj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20230701__20230930_z3rqsn7KySg6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240101__20240930_zi6oKd4Ur0k" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_490_20230101__20230930_ziYdGUR8IVl1" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_z1HLh8A6ol0d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(315,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(2,129,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(2,407,174&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(8,562,781&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PreferredStockDividendsIncomeStatementImpact_z9SRkPQAFTgd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in"&gt;Less: dividends on Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;106,133&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z2Laz0AXoFL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(365,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,145,260&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,513,307&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(8,578,381&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zIYPEMQYqyvd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 0.25in"&gt;Basic  weighted shares outstanding&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,085,911&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zWhlkw2sMqO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in"&gt;Dilutive effect from shares authorized&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0677"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0679"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zKsMZFHv59Cd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Diluted  weighted shares outstanding&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,976,227&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,085,911&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EarningsPerShareBasic_z9sweBeN5TT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Basic loss per share&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.57&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_zDknef3e0S2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Diluted loss per share&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.02&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.57&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="f400" xsi:nil="true" contextRef="c113" unitRef="usd1"/>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="f401" decimals="0" contextRef="c10" unitRef="usd1">6322.0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="f402" xsi:nil="true" contextRef="c115" unitRef="usd1"/>
  <us-gaap:ConcentrationRiskPercentage1 id="f403" decimals="INF" contextRef="c129" unitRef="pure">1.0</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f404" decimals="0" contextRef="c106" unitRef="usd1">8.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="f405" xsi:nil="true" contextRef="c117" unitRef="usd1"/>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="f406" decimals="0" contextRef="c1" unitRef="usd1">-420413.0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:ConvertibleNotesPayable id="f407" decimals="0" contextRef="c3" unitRef="usd1">360000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:IncomeTaxDisclosureTextBlock id="f408" contextRef="c5">&lt;p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zVLr9kMepYNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_82D_zEGGRULZuKQe"&gt;10. INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has federal and state net operating loss
carryforwards with a full valuation allowance against the deferred tax assets as of September 30, 2024. No income tax expense or benefit
was recorded for the three and nine months ended September 30, 2024 and 2023 due to the Companys net loss position.&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="f409" xsi:nil="true" contextRef="c86" unitRef="usd1"/>
  <us-gaap:NetIncomeLoss id="f410" xsi:nil="true" contextRef="c113" unitRef="usd1"/>
  <dei:EntityShellCompany id="f411" contextRef="c5">false</dei:EntityShellCompany>
  <us-gaap:NetIncomeLoss id="f412" xsi:nil="true" contextRef="c115" unitRef="usd1"/>
  <us-gaap:ScheduleOfOtherAssetsTableTextBlock id="f413" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_zfoVScwcfzvh" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid expenses (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20240930_zyGvo9yHgbyh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_490_20231231_zwKEr4Qn1BI8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December31,&lt;br/&gt; 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherPrepaidExpenseCurrent_iI_zLoVj2UokW11" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify"&gt;Prepaid marketing expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;63,750&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;9,871&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_zoi6RqGlT7Pe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,839&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_z0ISeRmotEz2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;81,589&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,943&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
  <us-gaap:NetIncomeLoss id="f414" xsi:nil="true" contextRef="c117" unitRef="usd1"/>
  <us-gaap:PrepaidExpenseCurrent id="f415" decimals="0" contextRef="c3" unitRef="usd1">81589.0</us-gaap:PrepaidExpenseCurrent>
  <vine:SponsorshipAgreementAnnualPayments id="f416" decimals="0" contextRef="c130" unitRef="usd1">103000.0</vine:SponsorshipAgreementAnnualPayments>
  <us-gaap:PreferredStockConvertibleConversionPrice id="f417" decimals="INF" contextRef="c131" unitRef="usd">0.1</us-gaap:PreferredStockConvertibleConversionPrice>
  <us-gaap:PreferredStockValue id="f418" decimals="0" contextRef="c100" unitRef="usd1">10.0</us-gaap:PreferredStockValue>
  <us-gaap:NetIncomeLoss id="f419" xsi:nil="true" contextRef="c121" unitRef="usd1"/>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f420" decimals="0" contextRef="c5" unitRef="usd1">126821.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <vine:AggregateSharePurchase id="f421" decimals="INF" contextRef="c23" unitRef="shares">10000.0</vine:AggregateSharePurchase>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="f422" xsi:nil="true" contextRef="c1" unitRef="usd1"/>
  <vine:SponsorshipSettlementAgreementAmountsPaid id="f423" decimals="0" contextRef="c132" unitRef="usd1">80000.0</vine:SponsorshipSettlementAgreementAmountsPaid>
  <us-gaap:LongTermDebtNoncurrent id="f424" decimals="0" contextRef="c3" unitRef="usd1">387500.0</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:InventoryWriteDown id="f425" xsi:nil="true" contextRef="c5" unitRef="usd1"/>
  <vine:SponsorshipAgreementAnnualPayments id="f426" decimals="0" contextRef="c133" unitRef="usd1">216000.0</vine:SponsorshipAgreementAnnualPayments>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="f427" decimals="0" contextRef="c1" unitRef="usd1">15600.0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ProvisionForDoubtfulAccounts id="f428" xsi:nil="true" contextRef="c5" unitRef="usd1"/>
  <vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued id="f429" decimals="0" contextRef="c56" unitRef="usd1">2543584.0</vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="f430" decimals="0" contextRef="c1" unitRef="usd1">-7973.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:ConcentrationRiskPercentage1 id="f431" decimals="INF" contextRef="c134" unitRef="pure">1.0</us-gaap:ConcentrationRiskPercentage1>
  <vine:SecuritiesPurchaseAgreementSeriesBPreferredStockTotalSharesAgreedToBePurchasedValue id="f432" decimals="0" contextRef="c135" unitRef="usd1">4100000.0</vine:SecuritiesPurchaseAgreementSeriesBPreferredStockTotalSharesAgreedToBePurchasedValue>
  <us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable id="f433" xsi:nil="true" contextRef="c5" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f434" decimals="0" contextRef="c136" unitRef="usd1">6407182.0</us-gaap:StockholdersEquity>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock id="f435" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zbGiAYJFhc0h" style="font: 11pt Aptos; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - Principal maturities of the Company's notes payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240930_zqpyjNwdCFRl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_zRFKzihWG1Rc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024 (three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"&gt;27,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_zhqS6pS5kwq7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_zyWjT9quV0cd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_z6lwtCFUZzZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtNoncurrent_iI_zi0wugYiCQBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;387,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <vine:GainOnSettlementOfSponsorshipSettlementAgreementArbitration id="f436" decimals="0" contextRef="c132" unitRef="usd1">370000.0</vine:GainOnSettlementOfSponsorshipSettlementAgreementArbitration>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="f437" xsi:nil="true" contextRef="c5" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f438" decimals="0" contextRef="c53" unitRef="usd1">-5613606.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f439" decimals="0" contextRef="c12" unitRef="usd1">1626.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <vine:ExpensesRelatedToSponsorshipAgreements id="f440" decimals="0" contextRef="c10" unitRef="usd1">0.0</vine:ExpensesRelatedToSponsorshipAgreements>
  <us-gaap:StockholdersEquity id="f441" decimals="0" contextRef="c123" unitRef="usd1">10.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f442" decimals="0" contextRef="c137" unitRef="usd1">-27719075.0</us-gaap:StockholdersEquity>
  <vine:NYSEListingRequirementPolicyPolicyTextBlock id="f443" contextRef="c5">&lt;p id="xdx_84F_ecustom--NYSEListingRequirementPolicyPolicyTextBlock_zBhHhpXVS0D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zsNbkbccVOu2"&gt;NYSE Listing Requirements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 8, 2023, the Company received a written
notice (the Notice) from NYSE American stating that it was not in compliance with Section 1003(a)(ii) of the NYSE American
Company Guide (the Company Guide), which requires a listed company that has reported losses from continuing operations and/or
net losses in three of its four most recent fiscal years to maintain at least $&lt;span id="xdx_90F_eus-gaap--StockholdersEquityOther_pn6n6_c20230908__20230908_zs4nw30z5Ix7"&gt;4&lt;/span&gt;million of stockholders equity. The Company
reported stockholders deficit of approximately $&lt;span id="xdx_909_eus-gaap--StockholdersEquity_iI_dxL_c20240930_znEQweZmpZIf" title="::XDX::-2401579%09"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;2.4&lt;/span&gt;&lt;/span&gt; million as of September 30, 2024 and have had losses from continuing operations
and/or net losses in each of the fiscal years ended December 31, 2020, 2021, 2022 and 2023. As required by the NYSE American, the Company
submitted a plan to the NYSE American on October 9, 2023 addressing actions it has taken and how it intends to regain compliance with
the continued listing standards within the required 18 month period ending March 8, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 21, 2023, the Company received notification
(the Acceptance Letter) from NYSE American that the Companys plan to regain compliance with NYSE Americans
listing standards was accepted.The Acceptance Letter also stated that the Company is not in compliance with Section 1003(a)(i) of
the Company Guide, which requires an issuer to have stockholders equity of $&lt;span id="xdx_90E_eus-gaap--StockholdersEquityOther_pin6_c20231101__20231121_z7960T8Y2Jh1"&gt;2.0&lt;/span&gt; million or more if it has reported losses from
continuing operations and/or net losses in two out of its three most recent fiscal years. NYSE American has granted the Company a plan
period through March 8, 2025 to regain compliance with Sections 1003(a)(i) and (ii) of the Company Guide. If the Company is not in compliance
with all continued listing standards by that date or if the Company does not make progress consistent with the plan during the plan period,
the Company will be subject to delisting proceedings.&lt;/p&gt;

</vine:NYSEListingRequirementPolicyPolicyTextBlock>
  <vine:IncreaseDecreaseInSettlementPayable id="f444" xsi:nil="true" contextRef="c5" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f445" decimals="0" contextRef="c126" unitRef="usd1">10.0</us-gaap:StockholdersEquity>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities id="f446" xsi:nil="true" contextRef="c5" unitRef="usd1"/>
  <vine:AccruedDividends id="f447" decimals="0" contextRef="c1" unitRef="usd1">15600.0</vine:AccruedDividends>
  <us-gaap:ProceedsFromNotesPayable id="f448" xsi:nil="true" contextRef="c1" unitRef="usd1"/>
  <us-gaap:EarningsPerShareBasic id="f449" decimals="INF" contextRef="c1" unitRef="usd">-0.57</us-gaap:EarningsPerShareBasic>
  <us-gaap:StockholdersEquity id="f450" decimals="0" contextRef="c138" unitRef="usd1">-28624777.0</us-gaap:StockholdersEquity>
  <vine:ExpensesRelatedToSponsorshipAgreements id="f451" decimals="0" contextRef="c31" unitRef="usd1">88000.0</vine:ExpensesRelatedToSponsorshipAgreements>
  <dei:EntityCommonStockSharesOutstanding id="f452" decimals="INF" contextRef="c139" unitRef="shares">15976227.0</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:NetIncomeLoss id="f453" decimals="0" contextRef="c67" unitRef="usd1">-4422297.0</us-gaap:NetIncomeLoss>
  <us-gaap:ProceedsFromConvertibleDebt id="f454" xsi:nil="true" contextRef="c1" unitRef="usd1"/>
  <us-gaap:AllocatedShareBasedCompensationExpense id="f455" decimals="0" contextRef="c140" unitRef="usd1">1626.0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:StockholdersEquity id="f456" decimals="0" contextRef="c128" unitRef="usd1">10.0</us-gaap:StockholdersEquity>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="f457" xsi:nil="true" contextRef="c141" unitRef="usd1"/>
  <dei:EntityFileNumber id="f458" contextRef="c5">001-41147</dei:EntityFileNumber>
  <us-gaap:ConcentrationRiskDisclosureTextBlock id="f459" contextRef="c5">&lt;p id="xdx_80E_eus-gaap--ConcentrationRiskDisclosureTextBlock_z3W1yZWhUOyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_82E_z9dg0ceTB4Ge"&gt;11.
SUPPLIER AND CUSTOMER CONCENTRATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has an agreement with an unrelated party
for various wine making activities, including production, bottling, labelling, and packaging. The Company pays certain storage, administrative
fees and taxes related to the purchased goods. There is no specified term of the agreement but continues as additional blanket sales orders
are issued. For the nine month periods ended September 30, 2024 and 2023, substantially all of the Companys inventory purchases
were from this supplier.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also engages with other suppliers for
the purchase of a select varietal of wine to be offered in limited quantities. There are no formal agreements due to the infrequency of
activity with these suppliers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A significant portion of the Companys
wholesale revenue in the first nine months of 2024 comes from three national distributor customers that operate in several markets.
For the nine-month period ended September 30, 2024, approximately &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240930__srt--MajorCustomersAxis__us-gaap--OtherCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zS49qqjdTHM7"&gt;79&lt;/span&gt;%
of the Companys wholesale revenue came from these three customers. For the three-month period ended September 30, 2024, the
customer concentration shifted to two new customers in addition to one customer from the nine-month period. For the three month
period ended September 30, 2024, these three customers accounted for &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__srt--MajorCustomersAxis__us-gaap--OtherCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNtETi9dtSrj"&gt;89&lt;/span&gt;%
of the Companys wholesale revenue. In 2023, for the three and nine month periods ended September 30, 2023, the concentration
included two customers from the 2024 periods along with one additional customer. For the three and nine month periods ended
September 30, 2023, these customers accounted for &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__srt--MajorCustomersAxis__us-gaap--OtherCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5qzxI0c5Lr5"&gt;96&lt;/span&gt;%
and &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__srt--MajorCustomersAxis__us-gaap--OtherCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUQRTIahRDpk"&gt;87&lt;/span&gt;%,
respectively, of the Companys wholesale revenue. At September 30, 2024, all of the customers mentioned above accounted for &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240930__srt--MajorCustomersAxis__us-gaap--OtherCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBZ3HzApRku3"&gt;66&lt;/span&gt;%
of accounts receivable.&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="f460" xsi:nil="true" contextRef="c142" unitRef="usd1"/>
  <vine:ExpensesRelatedToSponsorshipAgreements id="f461" decimals="0" contextRef="c5" unitRef="usd1">296000.0</vine:ExpensesRelatedToSponsorshipAgreements>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="f462" xsi:nil="true" contextRef="c5" unitRef="usd1"/>
  <us-gaap:SharesOutstanding id="f463" decimals="INF" contextRef="c143" unitRef="shares">8000.0</us-gaap:SharesOutstanding>
  <us-gaap:ConcentrationRiskPercentage1 id="f464" decimals="INF" contextRef="c144" unitRef="pure">1.0</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="f465" decimals="0" contextRef="c145" unitRef="usd1">6504.0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:PreferredStockSharesOutstanding id="f466" decimals="INF" contextRef="c146" unitRef="shares">9135.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="f467" xsi:nil="true" contextRef="c1" unitRef="usd1"/>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy id="f468" contextRef="c5">&lt;p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zczhzgadi3N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zbo1Ju9lNbhl"&gt;Accounts Receivable&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable consists of amounts owed to the
Company for sales of the Companys products on credit and are reported at net realizable value. Credit terms are extended to customers
in the normal course of business. The Company performs ongoing credit evaluations of its customers financial conditions. The Company
estimates allowances for future returns and doubtful accounts based upon historical experience and its evaluation of the current status
of receivables. Accounts considered uncollectible are written off against the allowance. As of September 30, 2024 and December 31, 2023
there was no allowance for doubtful accounts.&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f469" decimals="0" contextRef="c3" unitRef="usd1">-28990067.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <vine:ExpensesRelatedToSponsorshipAgreements id="f470" decimals="0" contextRef="c1" unitRef="usd1">265000.0</vine:ExpensesRelatedToSponsorshipAgreements>
  <us-gaap:Liabilities id="f471" decimals="0" contextRef="c3" unitRef="usd1">3383342.0</us-gaap:Liabilities>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f472" decimals="INF" contextRef="c31" unitRef="shares">15976227.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:AdvertisingExpense id="f473" decimals="0" contextRef="c1" unitRef="usd1">1400000.0</us-gaap:AdvertisingExpense>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f474" decimals="0" contextRef="c5" unitRef="usd1">-1346789.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EquityMethodInvestments id="f475" decimals="0" contextRef="c3" unitRef="usd1">500000.0</us-gaap:EquityMethodInvestments>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities id="f476" decimals="0" contextRef="c1" unitRef="usd1">29333.0</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:AllocatedShareBasedCompensationExpense id="f477" decimals="0" contextRef="c16" unitRef="usd1">4877.0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:PreferredStockSharesOutstanding id="f478" decimals="INF" contextRef="c29" unitRef="shares">0.0</us-gaap:PreferredStockSharesOutstanding>
  <vine:SecuritiesPurchaseAgreementSeriesBPreferredStockTotalSharesAgreedToBePurchased id="f479" decimals="INF" contextRef="c135" unitRef="shares">40865.0</vine:SecuritiesPurchaseAgreementSeriesBPreferredStockTotalSharesAgreedToBePurchased>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f480" decimals="0" contextRef="c1" unitRef="usd1">-4585403.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PrepaidExpenseCurrent id="f481" decimals="0" contextRef="c13" unitRef="usd1">42943.0</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PreferredStockDividendRatePercentage id="f482" decimals="INF" contextRef="c28" unitRef="pure">0.12</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f483" decimals="0" contextRef="c121" unitRef="usd1">1626.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:PrepaidInsurance id="f484" decimals="0" contextRef="c3" unitRef="usd1">17839.0</us-gaap:PrepaidInsurance>
  <us-gaap:CashEquivalentsAtCarryingValue id="f485" decimals="0" contextRef="c3" unitRef="usd1">72029.0</us-gaap:CashEquivalentsAtCarryingValue>
  <vine:GainOnSettlementOfSponsorshipAgreements id="f486" decimals="0" contextRef="c132" unitRef="usd1">370000.0</vine:GainOnSettlementOfSponsorshipAgreements>
  <us-gaap:RestrictedCashCurrent id="f487" decimals="0" contextRef="c3" unitRef="usd1">50039.0</us-gaap:RestrictedCashCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent id="f488" decimals="0" contextRef="c3" unitRef="usd1">185031.0</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:AllocatedShareBasedCompensationExpense id="f489" decimals="0" contextRef="c147" unitRef="usd1">145295.0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:StockholdersEquity id="f490" decimals="0" contextRef="c3" unitRef="usd1">-2401579.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f491" decimals="0" contextRef="c72" unitRef="usd1">1141.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockholdersEquity id="f492" decimals="0" contextRef="c42" unitRef="usd1">17017.0</us-gaap:StockholdersEquity>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="f493" xsi:nil="true" contextRef="c10" unitRef="shares"/>
  <us-gaap:AccountsReceivableNetCurrent id="f494" decimals="0" contextRef="c3" unitRef="usd1">45280.0</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="f495" decimals="0" contextRef="c3" unitRef="usd1">1381.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="f496" xsi:nil="true" contextRef="c31" unitRef="shares"/>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="f497" contextRef="c5">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zra9he1Q0wza" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zOrT1eD2ql69"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Companys financial statements have been
prepared and are presented in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial
statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair presentation
of the financial statements. In certain instances, amounts reported in prior period financial statements have been reclassified to conform
to the current financial statement presentation.&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:NotesPayableCurrent id="f498" decimals="0" contextRef="c3" unitRef="usd1">202469.0</us-gaap:NotesPayableCurrent>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f499" decimals="INF" contextRef="c3" unitRef="usd">0.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:SharesOutstanding id="f500" decimals="INF" contextRef="c148" unitRef="shares">940.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f501" decimals="0" contextRef="c149" unitRef="usd1">-1979884.0</us-gaap:StockholdersEquity>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="f502" xsi:nil="true" contextRef="c5" unitRef="shares"/>
  <dei:DocumentType id="f503" contextRef="c5">10-Q</dei:DocumentType>
  <dei:EntityRegistrantName id="f504" contextRef="c5">Fresh Vine Wine, Inc.</dei:EntityRegistrantName>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="f505" xsi:nil="true" contextRef="c1" unitRef="shares"/>
  <us-gaap:StockholdersEquity id="f506" decimals="0" contextRef="c150" unitRef="usd1">2359063.0</us-gaap:StockholdersEquity>
  <us-gaap:ConvertibleNotesPayable id="f507" xsi:nil="true" contextRef="c13" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f508" decimals="0" contextRef="c151" unitRef="usd1">-2169268.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="f509" decimals="0" contextRef="c10" unitRef="usd1">-365290.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f510" decimals="0" contextRef="c54" unitRef="usd1">257672.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:NetIncomeLoss id="f511" decimals="0" contextRef="c152" unitRef="usd1">-4422297.0</us-gaap:NetIncomeLoss>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent id="f512" xsi:nil="true" contextRef="c13" unitRef="usd1"/>
  <us-gaap:AdvertisingExpense id="f513" decimals="0" contextRef="c5" unitRef="usd1">334000.0</us-gaap:AdvertisingExpense>
  <us-gaap:SharesOutstanding id="f514" decimals="INF" contextRef="c153" unitRef="shares">9135.0</us-gaap:SharesOutstanding>
  <us-gaap:OtherPrepaidExpenseCurrent id="f515" decimals="0" contextRef="c3" unitRef="usd1">63750.0</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PreferredStockValue id="f516" decimals="0" contextRef="c146" unitRef="usd1">9.0</us-gaap:PreferredStockValue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f517" decimals="INF" contextRef="c154" unitRef="shares">2000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <vine:SecuritiesPurchaseAgreementSeriesBPreferredStockPurchasePricePerShare id="f518" decimals="INF" contextRef="c135" unitRef="usd">100.0</vine:SecuritiesPurchaseAgreementSeriesBPreferredStockPurchasePricePerShare>
  <us-gaap:NotesPayableCurrent id="f519" xsi:nil="true" contextRef="c13" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f520" decimals="0" contextRef="c143" unitRef="usd1">8.0</us-gaap:StockholdersEquity>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree id="f521" xsi:nil="true" contextRef="c3" unitRef="usd1"/>
  <us-gaap:InventoryPolicyTextBlock id="f522" contextRef="c5">&lt;p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zfzbaprInle5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zNbxOgX5TCFe"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories primarily include bottled wine which is
carried at the lower of cost (calculated using theaverage cost method) or net realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reduces the carrying value of inventories
that are obsolete or for which market conditions indicate cost will not be recovered to estimated net realizable value. The Companys
estimate of net realizable value is based on analysis and assumptions including, but not limited to, historical experience, future demand,
and market requirements. Reductions to the carrying value of inventories are recorded in cost of revenues.As of September 30, 2024
and December 31, 2023, the Company had recorded an inventory allowance of approximately $&lt;span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_c20240930_zB06j1bVUfe7"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_c20231231_zU7UwmT31BC5"&gt;112,000&lt;/span&gt;, respectively.&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour id="f523" xsi:nil="true" contextRef="c3" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f524" decimals="0" contextRef="c13" unitRef="usd1">-829519.0</us-gaap:StockholdersEquity>
  <us-gaap:EarningsPerShareDiluted id="f525" decimals="INF" contextRef="c10" unitRef="usd">-0.02</us-gaap:EarningsPerShareDiluted>
  <us-gaap:Liabilities id="f526" decimals="0" contextRef="c13" unitRef="usd1">2218776.0</us-gaap:Liabilities>
  <vine:GrossProceedsFromSaleOfPreferredStock id="f527" decimals="0" contextRef="c52" unitRef="usd1">914000.0</vine:GrossProceedsFromSaleOfPreferredStock>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear id="f528" decimals="0" contextRef="c3" unitRef="usd1">27500.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <us-gaap:ConcentrationRiskPercentage1 id="f529" decimals="INF" contextRef="c155" unitRef="pure">0.79</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f530" xsi:nil="true" contextRef="c156" unitRef="shares"/>
  <us-gaap:EquityMethodInvestments id="f531" decimals="0" contextRef="c13" unitRef="usd1">500000.0</us-gaap:EquityMethodInvestments>
  <us-gaap:NetIncomeLoss id="f532" decimals="0" contextRef="c47" unitRef="usd1">-2010824.0</us-gaap:NetIncomeLoss>
  <us-gaap:DividendsPreferredStock id="f533" decimals="0" contextRef="c104" unitRef="usd1">26133.0</us-gaap:DividendsPreferredStock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="f534" contextRef="c5">&lt;p id="xdx_80C_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zQiuWdKqWdZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_824_z9vmgBQJVJV3"&gt;6. ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accrued expenses consist of the following at:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zsuGmHtW5tdi" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued expenses (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20240930_zwzv5DPlu0Rk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20231231_zjlRsbqt6Zie" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--SponsorshipAgreementsCurrent_iI_zUYy5GVuZhgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;Sponsorship agreements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;832,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;608,818&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedCreditCardChargesCurrent_iI_zExPNiLLlpQg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued credit card charges&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockDividends_iI_ztdFNX1WCSu" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued Series A Preferred Stock dividends&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;148,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,867&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrent_iI_zZFHDmcF74al" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Legal and professional&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;47,924&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;125,704&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_zOVHVF4Wi0s1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;93,778&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27,059&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iI_zOMUOnluelV5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,125,942&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;810,723&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zL0Aw9upyLJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The sponsorship agreements related to marketing
contracts with unrelated parties within the sports and entertainment industry. The terms of the agreements ranged fromtwotofouryearswith
annual payments ranging from $&lt;span id="xdx_903_ecustom--SponsorshipAgreementAnnualPayments_c20240101__20240930__custom--AgreementAxis__custom--SponsorshipAgreementsMember__srt--RangeAxis__srt--MinimumMember_zM5tx1A7T61e"&gt;103,000&lt;/span&gt;to
$&lt;span id="xdx_906_ecustom--SponsorshipAgreementAnnualPayments_c20240101__20240930__custom--AgreementAxis__custom--SponsorshipAgreementsMember__srt--RangeAxis__srt--MaximumMember_zqyUWT5JcIMg"&gt;216,000&lt;/span&gt;per
agreement. All sponsorship agreements had terminated by the end of the second quarter of 2024. The total expense relating to these
agreements for the three months ended September 30, 2024 and 2023, was approximately $&lt;span id="xdx_909_ecustom--ExpensesRelatedToSponsorshipAgreements_c20240701__20240930_zVQhvMOEwJ02"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_90A_ecustom--ExpensesRelatedToSponsorshipAgreements_c20230701__20230930_zDg37lYm7HB5"&gt;88,000&lt;/span&gt;, respectively
and for the nine months ended September 30, 2024 and 2023, was approximately $&lt;span id="xdx_900_ecustom--ExpensesRelatedToSponsorshipAgreements_c20240101__20240930_zqk4XmtXkFBj"&gt;296,000&lt;/span&gt;
and $&lt;span id="xdx_90B_ecustom--ExpensesRelatedToSponsorshipAgreements_c20230101__20230930_zE4MyCPmDsEe"&gt;265,000&lt;/span&gt;,
respectively. Subsequent to September 30, 2024, the Company signed a settlement agreement resulting in a  gain on settlement of approximately $&lt;span id="xdx_90C_ecustom--GainOnSettlementOfSponsorshipAgreements_c20241001__20241114_zRb3AZ1WWCh"&gt;370,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accrued credit card charges primarily consist of warehouse,
shipping and other operating costs paid via Company credit card as a tool for managing cashflow.&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="f535" decimals="INF" contextRef="c157" unitRef="shares">1030000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f536" xsi:nil="true" contextRef="c141" unitRef="shares"/>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f537" decimals="0" contextRef="c1" unitRef="usd1">-171594.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock id="f538" contextRef="c5">&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z1eTg6ylUP7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zHbfUY0bniB9"&gt;Revenue recognition&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Companys total
revenue reflects the sale of wine domestically in the U.S. to wholesale distributors or DTC customers. Under ASC Topic 606,&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;(ASC 606), the Company recognizes revenue when control of the promised good is transferred
to the customer in an amount that reflects the consideration for which the Company is expected to be entitled to receive in exchange for
those products. Each contract includes a single performance obligation to transfer control of the product to the customer. Control is
transferred when the product is either shipped or delivered, depending on the shipping terms, at which point the Company recognizes the
transaction price for the product as revenue. The Company has elected to account for shipping and handling as a fulfillment activity,
with amounts billed to customers for shipping and handling included in total revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company also generates
revenue through membership in its wine club. Wine club members pay a monthly fee, which varies depending on level of membership, and are
entitled to receive quarterly shipments of wine, free shipping, and discounts on other wine and merchandise purchased. The Company recognizes
revenue for the monthly membership dues when the product is delivered. Any membership dues received before the product is delivered is
recorded as deferred revenue on the Companys balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;ASC 606 notes that when another
party is involved in providing goods or services to acustomer, the entity should determine whether the nature of its promise is
aperformance obligationto provide the specified goods or services itself (that is, the entity is a principal) or to arrange
for those goods or services to be provided by the other party (that is, the entity is an agent).The Company does not bear responsibility
for inventory losses and does not have pricing determination; therefore, the Company would be considered the agent and revenue should
be recognized as net sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Products are sold for cash or on credit terms. Credit
terms are established in accordance with local and industry practices, and typically require payment within 30-60 days of delivery or
shipment, as dictated by the terms of each agreement. The Company has elected the practical expedient to not account for significant financing
components as its payment terms are less than one year, and the Company determines the terms at contract inception. The Companys
sales terms do not allow for the right of return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The following table presents
the percentages of total revenue disaggregated by sales channels for the three and nine months ended September 30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--DisaggregationOfRevenueTableTextBlock_zN7gai0phEHi" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Percentages of total revenue disaggregated by sales channels (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three months ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine months ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%"&gt;Wholesale&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zHYqeVqRPaC2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;12.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zgAFI1it8t6h" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;87.8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_ze5cXGNEq8N6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;16.8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zJQepgzTwEda" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;75.1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Direct to consumer&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJXLSVk3nMn7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;87.7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpKaDWLgVk59" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z0DB2aexn1dj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwvplope6jV" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;24.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zKqmk03Ur8s8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zAdgsp416ha4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zimSnritT8pk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zjyhoOLYdSNd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zdNycTM1I64e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 5pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="f539" xsi:nil="true" contextRef="c156" unitRef="usd1"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f540" decimals="0" contextRef="c35" unitRef="usd1">111748.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f541" decimals="0" contextRef="c73" unitRef="usd1">373037.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <vine:GrossProceedsFromSaleOfPreferredStock id="f542" decimals="-6" contextRef="c82" unitRef="usd1">1000000.0</vine:GrossProceedsFromSaleOfPreferredStock>
  <us-gaap:ConcentrationRiskPercentage1 id="f543" decimals="INF" contextRef="c158" unitRef="pure">0.89</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f544" xsi:nil="true" contextRef="c159" unitRef="shares"/>
  <vine:IncreaseDecreaseInSettlementPayable id="f545" decimals="0" contextRef="c1" unitRef="usd1">-1250000.0</vine:IncreaseDecreaseInSettlementPayable>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="f546" contextRef="c5">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zjiUbtvtS6b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_824_zwsY25xefmVg"&gt;8. STOCKHOLDERS EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Rights offering&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the first quarter of 2023, the Company
distributed, at no charge to holders of the Companys common stock, non-transferable subscription rights to purchase up to an
aggregate of&lt;span id="xdx_900_eus-gaap--TemporaryEquitySharesSubscribedButUnissued_iI_c20230331_zHfsayYzxPSl"&gt;6,366,129&lt;/span&gt;Units.
Each Unit consisted of&lt;span id="xdx_90C_eus-gaap--CommonUnitIssued_iI_dc_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlhNZ2hkGlYd"&gt;one&lt;/span&gt;share
of our common stock and a warrant (Rights Offering Warrants) to purchase&lt;span id="xdx_90A_eus-gaap--CommonUnitIssued_iI_dc_c20230331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z66XEciGkzB1"&gt;one&lt;/span&gt;share
of our common stock. The Rights Offering Warrants were exercisable immediately, expirefive
yearsfrom the date of issuance and have an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331_zjHpA85sFPqg"&gt;1.25&lt;/span&gt;per
share. For each share of common stock held by a stockholder of the Company on February 22, 2023, the record date of the Rights
Offering, such stockholder received&lt;span id="xdx_907_ecustom--StockholderReceivedSubscriptionRights_iI_pid_c20230222_zhtkI6XOMRJ8"&gt;0.5&lt;/span&gt;subscription
rights. Each whole subscription right allowed the holder thereof to subscribe to purchase one Unit, which the Company refers to as
the basic subscription right, at a subscription price of $&lt;span id="xdx_905_ecustom--StockholdersSubscriptionPerShare_iI_c20230222_zf1VAF5AsaGj"&gt;1.00&lt;/span&gt;per
Unit. In addition, any holder of subscription rights exercising his, her or its basic subscription right in full was eligible to
subscribe to purchase additional Units that remained unsubscribed in the Rights Offering at the same subscription price per Unit
that applied to the basic subscription right, subject to proration among participants exercising their over-subscription privilege,
which the Company refers to as the over-subscription privilege. Upon the closing of the Rights Offering, which occurred on March 14,
2023, the Company issued&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230314__20230314__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zqmUjhbvYuM3"&gt;3,143,969&lt;/span&gt;shares
of common stock and&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230314__20230314__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzsH2GKvQzhb"&gt;3,143,969&lt;/span&gt;Rights
Offering Warrants and received aggregate gross cash proceeds of approximately $&lt;span id="xdx_90A_eus-gaap--DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_pin6_c20230314__20230314_zVHR4kSyVGU5"&gt;3.14&lt;/span&gt;million.
After deducting dealer-manager fees and other fees and expenses related to the Rights Offering, the Company received net proceeds of
approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromFeesReceived_pin6_c20230101__20230930_zkmhhkWFM7d8"&gt;2.6&lt;/span&gt;million.
If exercised, additional gross proceeds of up to approximately $&lt;span id="xdx_90C_ecustom--SaleLeasebackTransactionGrossProceedInvestingActivities_pin6_c20240101__20240930_zzDLszLzUpgf"&gt;3.93&lt;/span&gt;million
may be received through the exercise of warrants issued in the Rights Offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On July 27,
2023, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation of Preferences, Rights and Limitations
of Series A Convertible Preferred Stock, par value $&lt;span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230727__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zIe06NapL7Bj"&gt;0.001&lt;/span&gt; per share (the Series A Stock), which was amended on August 1,
2023 prior to the issuance of any shares of Series A Stock by filing Amendment No. 1 thereto (as so amended, the Certificate).
The Certificate designates &lt;span id="xdx_905_ecustom--PreferredStockSharesDesignates_c20230727__20230727__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfZEdEHO40f2"&gt;10,000&lt;/span&gt; shares of the Companys undesignated preferred stock as Series A Stock and establishes the rights
and preferences of Series A Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 2, 2023, the Company entered into a Securities
Purchase Agreement with two accredited investors (the Purchasers) pursuant to which the Company agreed to issue and sell
in a private placement (the Offering) shares of Series A Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Securities Purchase Agreement, the
Purchasers collectively agreed to purchase up to&lt;span id="xdx_908_ecustom--AggregateSharePurchase_iI_c20230930_zGELK5fk8uCc"&gt;10,000&lt;/span&gt;shares of Series A Stock at a per share purchase price equal to $&lt;span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__custom--AgreementAxis__custom--SecurityPurchaseAgreementMember_z7NC0Yk6HFxc"&gt;100.00&lt;/span&gt;(the
Stated Value), for total gross proceeds of up to $&lt;span id="xdx_901_ecustom--PurchaseOfShareValueOfGrossProceeds_pin6_c20230101__20230930__custom--AgreementAxis__custom--SecurityPurchaseAgreementMember_zj5JsjPJMoW4"&gt;1.0&lt;/span&gt;million. The Purchasers agreed to purchase&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230802__20230802__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zF9T9r444mA"&gt;4,000&lt;/span&gt;shares
of Series A Stock for an aggregate purchase price of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20230802__20230802__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z1W3bjRUjRkd"&gt;400,000&lt;/span&gt;at an initial closing of the Offering (the Initial Closing),
which occurred on August 2, 2023. The Securities Purchase Agreement provided that the Company will issue and sell to the Purchasers, and
the Purchasers will purchase, an additional&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230907__20230907_zza0iqHXKA1f"&gt;4,000&lt;/span&gt;shares of Series A Stock at a second closing (the Second Closing),
which occurred on September 7, 2023. The Securities Purchase Agreement provided that the Company will issue and sell to the Purchasers,
and the Purchasers will purchase, an additional&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231201__20231201_zgz2jsHdeB03"&gt;2,000&lt;/span&gt;shares of Series A Stock at an optional closing (the Optional Closing),
which occurred on December 1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each share of Series A Stock is convertible, at any
time and from time to time from and after the date of the Initial Closing at the option of the holder thereof, into the number of shares
of common stock (Conversion Shares) calculated by dividing the Stated Value by a conversion price (the Conversion
Price) of $&lt;span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAjSVsUXocu5"&gt;0.10&lt;/span&gt;. However, if the Companys common stock fails to continue to be listed or quoted for trading on a stock exchange,
then the Conversion Price thereafter will mean the lesser of (i) $&lt;span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp5BHj3fK2Vc"&gt;0.10&lt;/span&gt;, or (ii) the closing sale price of the common stock on the trading
day immediately preceding the conversion date; provided that the Conversion Price shall not be less than $&lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20240930_znCalWIo3iv5"&gt;0.05&lt;/span&gt;(the Floor
Price). The Conversion Price is subject to standard adjustments based stock splits, stock dividends, stock combinations and the
like, and the Floor Price is also subject to anti-dilution adjustments resulting from future offerings of common stock (or common stock
equivalents) at a price less than the prevailing Conversion Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon any liquidation, dissolution or winding-up of
the Company, whether voluntary or involuntary (a Liquidation), the Holders shall (i) first be entitled to receive out of
the assets, whether capital or surplus, of the Company an amount equal to&lt;span id="xdx_909_ecustom--CapitalOrSurplusOfPercentage_dp_c20240101__20240930_zVjzmwWDlcub"&gt;150&lt;/span&gt;% times the Stated Value for each share of Series A
Stock before any distribution or payment shall be made to the holders of any junior securities and (ii) then be entitled to participate
in the distribution of remaining assets with the holders of common stock on an as-if-converted to common stock basis (disregarding for
such purposes any conversion limitations).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may redeem (i) up to&lt;span id="xdx_901_ecustom--StockIssuedAndOutstanding_dp_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemablePreferredStockMember_z8kUDRs51K44"&gt;75&lt;/span&gt;% of the issued
and outstanding shares of Series A Stock for a price per share equal to&lt;span id="xdx_90B_ecustom--PricePerShareOfRedemptionPercentage_dp_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemablePreferredStockMember_zEJ6SFpONSIh"&gt;150&lt;/span&gt;% of the Stated Value thereof if such redemption occurs
within six months from the date of issuance, and (ii) up to&lt;span id="xdx_903_ecustom--StockIssuedAndOutstanding_dp_c20240101__20240930_zXzmvBBPhGE6"&gt;50&lt;/span&gt;% of the issued and outstanding shares of Series A Stock for a price
per share equal to&lt;span id="xdx_90A_ecustom--PricePerShareOfRedemptionPercentage_dp_c20240101__20240930_zfW2pjfVYYla"&gt;200&lt;/span&gt;% of the Stated Value thereof if such redemption occurs after six months but before the expiration of twelve
months from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each holder of a share of Series A Stock is entitled
to receive dividends payable, subject to certain conditions, in cash or shares of common stock (Dividend Shares) valued
as either (i) the then applicable Conversion Price, or (ii)&lt;span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_dp_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztYBcYlSzK6k"&gt;50&lt;/span&gt;% of the then current market price of the Companys common stock,
at the dividend rate of&lt;span id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_dp_c20240101__20240630_z0Bgil7Memye"&gt;12&lt;/span&gt;% per annum. Dividends are cumulative and will be payable on July 31st of each year. If the dividend is
not paid as of July 31, 2024, the dividend rate increases to &lt;span id="xdx_90E_ecustom--PreferredStockDividendRatePercentage2_dp_c20240701__20240930_z1bScUeeS6Ml"&gt;24&lt;/span&gt;% per annum. However, the Company may not pay dividends by issuing Dividend
Shares if and to the extent that the issuance of such Dividend Shares, when added to all Conversion Shares previously issued upon prior
conversions of Series A Stock and previously issued Dividend Shares (if any), would exceed the Exchange Share Cap or result in a Series
A Stock holder beneficially owning shares of common stock in excess of the Individual Holder Share Cap, in each case unless the Company
obtains stockholder approval for such issuances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The shares of Series A Stock will vote with the common
stock as a single class on all matters submitted to a vote of stockholders of the Company other than any proposal to approve the issuance
of shares of common stock in excess of the Exchange Share Cap or the Individual Holder Share Cap. The Preferred Shares will vote on an
as-converted to common stock basis, taking into account the conversion limitations resulting from the Exchange Share Cap and the Individual
Holder Share Cap, if and as applicable; however, solely for purposes of determining voting rights, the Conversion Price shall be equal
to the most recent closing sale price of the common stock as of the execution and delivery of the Securities Purchase Agreement, which
was $&lt;span id="xdx_907_ecustom--ClosingPriceOfCommonStockAsExecutionAndDelivery_c20240101__20240930_zwDxcdcmU7ci"&gt;0.47&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There issuance activity of the Series A Stock is summarized
below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfSeriesAStockIssuanceActivityTableTextBlock_z3lUrqegpQO" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Issuance activity of Series A Stock (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20240701__20240930_zIx46TRIyBC" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20230701__20230930_zGsshOZB3gWc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49F_20240101__20240930_zBPolax1dGQg" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20230101__20230930_zCFSlFohRSX4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1bV0vnCQM77" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;Series A preferred stock shares issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0834"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFuCJUjF5xEf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net proceeds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;750,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;750,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zRcayvIVexB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Series A Stock meets the requirements for permanent
equity classification as prescribed by the authoritative guidance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes accrued dividends that
the Company is legally obligated to pay:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDividendsPayableTextBlock_znzFEg4AnOlb" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued dividends that the Company is legally obligated to pay (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20240101__20240930_zdCzWuqNG8b" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49C_20230101__20231231_zxCYWQYCIBDb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December31,&lt;br/&gt; 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DividendsPreferredStockStock_zsxnvZHR6G8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify"&gt;Series A preferred stock&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;148,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;41,867&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zkIJr2yzj4r9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On March 14,
2024, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation of Preferences, Rights and Limitations
of Series B Convertible Preferred Stock, par value $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240314__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zuP9bc9Q9fc4"&gt;0.001&lt;/span&gt; per share (the Series B Stock). The Certificate designates &lt;span id="xdx_90F_ecustom--PreferredStockSharesDesignates_c20240314__20240314__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zXodWfkLCDEf"&gt;50,000&lt;/span&gt;
shares of the Companys undesignated preferred stock as Series B Stock and establishes the rights and preferences of Series B Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the first and second quarters of 2024, the
Company entered into multiple Securities Purchase Agreements with accredited investors pursuant to which the Company agreed to issue and
sell in a private placement (the Series B Offering) shares of Series B Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Securities Purchase Agreement, each
share of Series B Stock will have a stated value equal to $&lt;span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240930__custom--AgreementAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zPlkU6YWZF27"&gt;100.00&lt;/span&gt;(the Stated Value). As of September 30, 2024, &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240930_zVfUKjNB0Yzl"&gt;9,135&lt;/span&gt;
shares of Series B Stock had been sold for a total in gross proceeds of $&lt;span id="xdx_905_ecustom--GrossProceeds_c20240101__20240930_zINetziJavl6"&gt;913,500&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Each share of
Series B Stock shall be convertible at the option of the holder thereof into the number of shares common stock (Conversion Shares)
calculated by dividing the Stated Value by the Conversion Price (the Conversion Ratio)(subject to the limitations described
below). For such purposes, the Conversion Price means $&lt;span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zn8YXcxxOCag"&gt;0.45&lt;/span&gt;. However, if the Companys common stock fails to continue
to be listed or quoted for trading on a stock exchange (currently, the NYSE American), then the Conversion Price thereafter
will mean the lesser of (i) $&lt;span id="xdx_90C_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240101__20240930_zqxAWdmm06C3"&gt;0.45&lt;/span&gt;, or (ii) the closing sale price of the common stock on the trading day immediately preceding the conversion
date; provided that the Conversion Price shall not be less than $&lt;span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20240101__20240930_zD0wdabiOek3"&gt;0.05&lt;/span&gt; (the Floor Price). The Conversion Price is subject
to standard adjustments based stock splits, stock dividends, stock combinations and the like, and the Floor Price is also subject to anti-dilution
adjustments resulting from future offerings of common stock (or common stock equivalents) at a price less than the prevailing Floor Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Except for stock
dividends or distributions for which adjustments are to be made pursuant to antidilution provisions of the Certificate, holders of Series
B Stock shall be entitled to receive dividends on shares of Series B Stock equal (on an as-if-converted-to-Common-Stock basis) to and
in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
may redeem (i) up to &lt;span id="xdx_901_ecustom--StockIssuedAndOutstanding_dp_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziDDnlcKbaWe"&gt;75&lt;/span&gt;% of the issued and outstanding Series B Preferred Shares for a price per share equal to &lt;span id="xdx_908_ecustom--PricePerShareOfRedemptionPercentage_dp_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zXwnbirtXkAb"&gt;150&lt;/span&gt;% of the Stated Value
thereof if such redemption occurs within six months from the date of issuance, and (ii) up to &lt;span id="xdx_90C_ecustom--StockIssuedAndOutstanding_dp_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z2fVeyo2RyIc"&gt;50&lt;/span&gt;% of the issued and outstanding Series
B Preferred Shares for a price per share equal to &lt;span id="xdx_90D_ecustom--PerSharePercentage_dp_c20240101__20240930_zMOswMyVBxvj"&gt;200&lt;/span&gt;% of the Stated Value thereof if such redemption occurs after six months but before
the expiration of twelve months from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Series B
Stock will vote with the common stock and the Series A Convertible Preferred Stock as a single class on all matters submitted to a vote
of stockholders of the Company other than any proposal to approve the issuance of shares of common stock upon the conversion of Series
B Stock in excess of the Exchange Share Cap or the Individual Holder Share Cap. The shares of Series B Stock will vote on an as-converted
to common stock basis, taking into account the conversion limitations resulting from the Exchange Share Cap and the Individual Holder
Share Cap, if and as applicable; however, solely for purposes of determining voting rights, the Conversion Price with respect to each
share of Series B Stock shall be equal to the most recent closing sale price of the common stock as of the execution and delivery of the
securities purchase agreement or other subscription or similar agreement pursuant to which such share of Series B Stock was issued by
the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company previously engaged The Oak Ridge Financial
Services Group, Inc. to serve as a financial advisor to the Company in connection with capital raising activities. In connection with
the Series B Offering, the Company has agreed to pay the Oak Ridge a cash fee equal to &lt;span id="xdx_90A_ecustom--PercentageOfGrossProceed_pid_dp_c20240101__20240930_znrTMx8xelM3"&gt;8.0&lt;/span&gt;% of the gross proceeds received by the Company
in the Offering, in addition to reimbursing Oak Ridge for its out-of-pocket expenses. In addition, the Company issued to Oak Ridge (or
its designee) seven-year warrants to purchase up to a total of &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930_ztDYDLYSyqi4"&gt;300,000&lt;/span&gt; shares of the Companys common stock at an exercise price
equal to $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930_zo9zGJecUff1"&gt;0.50&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The issuance activity of the Series B Stock is summarized
below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfSeriesBStockIssuanceActivityTableTextBlock_zSUCa9mpSEXc" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Issuance activity of Series B Stock (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240701__20240930_zPzsfdvsaAR" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20230701__20230930_zLPJjngoWH77" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20240101__20240930_zzdeGNlKvrB4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20230101__20230930_zpwIjqJIEYRa" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three months ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine months ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWzV4imQqCj3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;Series B preferred stock shares issued&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;9,135&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0867"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztcBn91r8Qhb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net proceeds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;805,017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0872"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z5IGADYzBvN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Series B Stock meets the requirements for permanent
equity classification as prescribed by the authoritative guidance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Third Party Vendor Engagements and Related
Founder Share Forfeitures&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2022, Rick Nechio and Damian Novak, two
of the Companys founders, together agreed to forfeit and transfer back to the Company without consideration a total of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20220101__20221231_zYtSyeGgWAH2"&gt;970,000&lt;/span&gt;
shares of common stock of the Company held by them, to enable the Company to preserve cash by issuing such number of shares to certain
of the Companys service providing vendors without subjecting the Companys other stockholders to dilution therefrom. Also
in December 2022, the Company entered into agreements to issue &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemablePreferredStockMember_z6ghLloURInc"&gt;970,000&lt;/span&gt; shares to such vendors in transactions exempt from the registration
requirements of the Securities Act of 1933, as amended (the Securities Act). Recipients of the shares included our third-party
sales and distribution management service provider, as well as certain advertising, public relations, consulting, and legal service providers.
Pursuant to agreements with certain of these vendors, the Company has agreed to issue up to an additional &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231_zyBJL6rNWmnk"&gt;1,030,000&lt;/span&gt; shares of common stock
upon the Company achieving specified revenue-related performance objectives within identified timeframes. Equity-based compensation expense
related to the additional shares subject to revenue-related performance objectives was not material to the 2024 or 2023 financial statements.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <vine:CapitalOrSurplusOfPercentage id="f547" decimals="INF" contextRef="c5" unitRef="pure">1.5</vine:CapitalOrSurplusOfPercentage>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f548" xsi:nil="true" contextRef="c160" unitRef="shares"/>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="f549" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zsuGmHtW5tdi" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued expenses (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20240930_zwzv5DPlu0Rk" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20231231_zjlRsbqt6Zie" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--SponsorshipAgreementsCurrent_iI_zUYy5GVuZhgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;Sponsorship agreements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;832,660&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;608,818&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedCreditCardChargesCurrent_iI_zExPNiLLlpQg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued credit card charges&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--StockDividends_iI_ztdFNX1WCSu" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued Series A Preferred Stock dividends&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;148,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,867&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedProfessionalFeesCurrent_iI_zZFHDmcF74al" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Legal and professional&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;47,924&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;125,704&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_zOVHVF4Wi0s1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;93,778&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27,059&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iI_zOMUOnluelV5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,125,942&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;810,723&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ProceedsFromConvertibleDebt id="f550" decimals="0" contextRef="c10" unitRef="usd1">300000.0</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:AdvertisingExpense id="f551" decimals="0" contextRef="c31" unitRef="usd1">258000.0</us-gaap:AdvertisingExpense>
  <us-gaap:ConcentrationRiskPercentage1 id="f552" decimals="INF" contextRef="c161" unitRef="pure">0.96</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f553" xsi:nil="true" contextRef="c142" unitRef="shares"/>
  <us-gaap:AccountsReceivableNetCurrent id="f554" decimals="0" contextRef="c13" unitRef="usd1">172101.0</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:SharesOutstanding id="f555" decimals="INF" contextRef="c162" unitRef="shares">15876226.0</us-gaap:SharesOutstanding>
  <us-gaap:PreferredStockDividendRatePercentage id="f556" decimals="INF" contextRef="c10" unitRef="pure">0.24</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f557" decimals="INF" contextRef="c163" unitRef="shares">3143969.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f558" decimals="INF" contextRef="c13" unitRef="shares">446559.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="f559" xsi:nil="true" contextRef="c159" unitRef="usd1"/>
  <us-gaap:AssetsCurrent id="f560" decimals="0" contextRef="c3" unitRef="usd1">481763.0</us-gaap:AssetsCurrent>
  <us-gaap:StockholdersEquity id="f561" decimals="0" contextRef="c148" unitRef="usd1">1.0</us-gaap:StockholdersEquity>
  <vine:SecuritiesPurchaseAgreementSeriesBPreferredStockShares id="f562" decimals="INF" contextRef="c135" unitRef="shares">40000.0</vine:SecuritiesPurchaseAgreementSeriesBPreferredStockShares>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="f563" xsi:nil="true" contextRef="c160" unitRef="usd1"/>
  <vine:GrossProceedsFromSaleOfPreferredStock id="f564" decimals="0" contextRef="c132" unitRef="usd1">4100000.0</vine:GrossProceedsFromSaleOfPreferredStock>
  <us-gaap:ConcentrationRiskPercentage1 id="f565" decimals="INF" contextRef="c164" unitRef="pure">0.87</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f566" decimals="INF" contextRef="c165" unitRef="shares">300000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f567" decimals="INF" contextRef="c166" unitRef="shares">4000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="f568" xsi:nil="true" contextRef="c16" unitRef="shares"/>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="f569" decimals="0" contextRef="c31" unitRef="usd1">-2145260.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="f570" xsi:nil="true" contextRef="c16" unitRef="shares"/>
  <vine:TerminationOfAgreementAndPlanOfMergerPolicyTextBlock id="f571" contextRef="c5">&lt;p id="xdx_840_ecustom--TerminationOfAgreementAndPlanOfMergerPolicyTextBlock_zbB2bM8Wjpsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_z5iuOZValBk9"&gt;Termination of Agreement and Plan of Merger
with Notes Live&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 25, 2024,the Company, FVW Merger
Sub, Inc., a Colorado corporation and a wholly-owned subsidiary ofthe Company(Merger Sub), and Notes, Live,
Inc., a Colorado corporation (Notes Live), entered into an Agreement and Plan of Merger (the Merger Agreement)
pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement,
Merger Sub will merge with and into Notes Live, with Notes Live continuing as a wholly-owned subsidiary of the Company and the surviving
corporation of the merger (the Merger). On July 31, 2024, the Merger Agreement was terminated.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</vine:TerminationOfAgreementAndPlanOfMergerPolicyTextBlock>
  <vine:SecuredConvertiblePromissoryNotesPrincipalAmount id="f572" decimals="0" contextRef="c15" unitRef="usd1">600000.0</vine:SecuredConvertiblePromissoryNotesPrincipalAmount>
  <us-gaap:StockholdersEquity id="f573" decimals="0" contextRef="c153" unitRef="usd1">9.0</us-gaap:StockholdersEquity>
  <us-gaap:ProceedsFromConvertibleDebt id="f574" decimals="0" contextRef="c132" unitRef="usd1">200000.0</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:InvestmentOwnedBalanceShares id="f575" decimals="INF" contextRef="c13" unitRef="shares">50000.0</us-gaap:InvestmentOwnedBalanceShares>
  <us-gaap:DebtDisclosureTextBlock id="f576" contextRef="c5">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zMNEuo99gB45" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_823_zI0tTzlLs6T1"&gt;7. NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Set forth below is a summary of the Companys outstanding debts as
of September 30, 2024 and December 31, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zwCOQx32RMCb" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of the Company's outstanding debts (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240930_zWU12W6va5G5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_490_20231231_zrSrxkrbhuO" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_zmJiZBJD8rng" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;Convertible notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_zQi2fQQuRKw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: discount on convertible notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(185,031&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ConvertibleNotesPayableCurrent_iI_zoolLujESBd7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total convertible notes, net of discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;174,969&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0763"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherNotesPayableCurrent_iI_zt5a4Ugxhtm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Other note payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NotesPayableCurrent_iI_zfQpDJZti5Gk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;202,469&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z20GVxsn1ZZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2024, the Company entered into
Securities Purchase Agreements (the Securities Purchase Agreements) with two accredited investors, pursuant to which
the Company agreed to sell up to an aggregate principal amount of $&lt;span id="xdx_90A_ecustom--SecuredConvertiblePromissoryNotesPrincipalAmount_c20241001__20241031_zasPuqcGwp4a"&gt;600,000&lt;/span&gt;
of secured convertible promissory notes (Notes) that will be convertible into shares of the Companys common
stock, par value $&lt;span id="xdx_908_ecustom--SecuredConvertiblePromissoryNotesConversionPrice_c20241001__20241031_zP8QXN6aE9ye"&gt;0.001&lt;/span&gt;
per share and warrants. The Notes were issued with original issuance discount of &lt;span id="xdx_90A_ecustom--SecuredConvertiblePromissoryNotesOriginalIssueDiscountRate_dp_c20241001__20241031_zqmGOtqZOJdj"&gt;20&lt;/span&gt;%,
resulting in gross proceeds of $&lt;span id="xdx_90B_ecustom--GrossProceedsFromSecuredConvertiblePromissoryNotes_c20241001__20241031_zVDBzzwsxdVg"&gt;500,000&lt;/span&gt;
to the Company. The Notes bear no interest unless an event of default occurs, and mature on April 4, 2025. The Notes may be prepaid
without penalty. Each Note is convertible into common stock at a conversion price equal to $&lt;span id="xdx_90E_ecustom--SecuredConvertiblePromissoryNotesConversionPriceCommonStock_c20241001__20241031_zFtfzD1gZ3E5"&gt;0.40&lt;/span&gt;.
In September 2024 the Company received $&lt;span id="xdx_90D_ecustom--ProceedsFromSecuredConvertiblePromissoryNotes_c20240901__20240930_znjoMs6SZvph"&gt;300,000&lt;/span&gt;
related to these Notes and after reviewing the transaction details determined it was considered a reportable subsequent event and
recorded the transaction as of September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Securities Purchase Agreements,
the Company issued warrants with an exercise period of five years to purchase up to &lt;span id="xdx_903_ecustom--WarrantsIssuedPursuantToSecuritiesPurchaseAgreements_c20241001__20241031_zNLbBFa60MZd"&gt;740,000&lt;/span&gt; shares of the common stock at an exercise
price of $&lt;span id="xdx_90C_ecustom--WarrantsIssuedPursuantToSecuritiesPurchaseAgreementsExercisePrice_c20241001__20241031_zzbYdkmlfKpg"&gt;0.40&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviewed the warrants in connection with
the Securities Purchase Agreements under ASC 815 and concluded that the warrants are not in scope of ASC 480 and are not subject to the
derivative guidance under ASC 815. Accordingly, the warrants were equity classified. As such the principal value of the Notes was allocated
using the relative fair value basis of all instruments. As the warrants were issued with another instrument the purchase price was allocated
using the relative fair value method (i.e., warrants at its fair value and the Notes at its principal value allocated using the relative
fair value of the proceeds received an applied proportionally to the equity classified warrants and Notes).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2024, the Company received cash
proceeds of $&lt;span id="xdx_90E_ecustom--ProceedsFromSecuredConvertiblePromissoryNotes_c20240101__20240930_zDxiz6M0f3si"&gt;300,000&lt;/span&gt;. As such the Company recorded the fair value of the warrants of $&lt;span id="xdx_905_ecustom--FairValueOfWarrantsRecorded_iI_c20240930_zqpKW5iySAw6"&gt;131,353&lt;/span&gt; based on the relative value basis. The Company
recorded original issue discount of $&lt;span id="xdx_90C_ecustom--OriginalIssueDiscountRecorded_iI_c20240930_zg5BA7ZYfBN2"&gt;191,353&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2024, the Notes net of unamortized
debt discount was $&lt;span id="xdx_909_ecustom--DebtInstrumentNetOfUnamortizedDiscountCurrent_iI_c20240930_z0mOQ2nXOdda"&gt;174,969&lt;/span&gt;. The Company recognized $&lt;span id="xdx_90E_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20240701__20240930_zCMFsl8hCcKc"&gt;6,322&lt;/span&gt; of the amortized debt discount in interest expense for the three months ended
September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Principal maturities of the Companys notes payable are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zbGiAYJFhc0h" style="font: 11pt Aptos; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - Principal maturities of the Company's notes payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240930_zqpyjNwdCFRl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_zRFKzihWG1Rc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024 (three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"&gt;27,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_zhqS6pS5kwq7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_zyWjT9quV0cd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_z6lwtCFUZzZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtNoncurrent_iI_zi0wugYiCQBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;387,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zHbHcEs9eUCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 5pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 id="f577" decimals="INF" contextRef="c167" unitRef="pure">0.66</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="f578" xsi:nil="true" contextRef="c168" unitRef="shares"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="f579" decimals="INF" contextRef="c169" unitRef="shares">1030000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f580" decimals="INF" contextRef="c20" unitRef="shares">444000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms id="f581" xsi:nil="true" contextRef="c16"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="f582" xsi:nil="true" contextRef="c170" unitRef="shares"/>
  <vine:SecuredConvertiblePromissoryNotesConversionPrice id="f583" decimals="INF" contextRef="c15" unitRef="usd">0.001</vine:SecuredConvertiblePromissoryNotesConversionPrice>
  <us-gaap:LossContingencyDamagesAwardedValue id="f584" decimals="2" contextRef="c171" unitRef="usd1">585976.25</us-gaap:LossContingencyDamagesAwardedValue>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f585" decimals="INF" contextRef="c5" unitRef="shares">15976227.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <vine:MaximumFundsToBeRaisedThroughEquitySalesAndDebtSecuritiesPursuantToBusinessCombinationAgreement id="f586" decimals="0" contextRef="c132" unitRef="usd1">10000000.0</vine:MaximumFundsToBeRaisedThroughEquitySalesAndDebtSecuritiesPursuantToBusinessCombinationAgreement>
  <vine:PreferredStockSharesDesignates id="f587" decimals="INF" contextRef="c172" unitRef="shares">10000.0</vine:PreferredStockSharesDesignates>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="f588" contextRef="c5">&lt;p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHx81SOEaZbj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_82D_zefVsnkI6Udd"&gt;12. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License agreements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During March 2021, the Company entered into two license
agreements with certain equity investors for marketing and advertising services. These two agreements were terminated during the third
quarter of 2023 and the remaining prepaid license fee was expensed. The net expense relating to the agreements was $&lt;span id="xdx_909_ecustom--NetExpenseRelatingToAgreements_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember_z4wmfjanQI9f"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--NetExpenseRelatingToAgreements_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember_zPDoDYVbDG84"&gt;89,333&lt;/span&gt; for
the three months ended September 30, 2024 and 2023, respectively and $&lt;span id="xdx_903_ecustom--NetExpenseRelatingToAgreements_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember_zxqNUaAXTOqb"&gt;0&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--NetExpenseRelatingToAgreements_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember_zVUKCMgxonUg"&gt;329,333&lt;/span&gt; for the nine months ended September 30, 2024 and
2023, respectively. The Company had accrued approximately $&lt;span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember_zTMLqRoqiz44"&gt;&lt;span id="xdx_90C_eus-gaap--AccruedLiabilitiesCurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember_zMHGI6M5ybL9"&gt;309,000&lt;/span&gt;&lt;/span&gt; for these license agreements as of September 30, 2024 and December
31, 2023.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="f589" xsi:nil="true" contextRef="c170" unitRef="shares"/>
  <us-gaap:RestrictedCashCurrent id="f590" decimals="0" contextRef="c13" unitRef="usd1">100000.0</us-gaap:RestrictedCashCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="f591" xsi:nil="true" contextRef="c170" unitRef="shares"/>
  <us-gaap:EarningsPerShareDiluted id="f592" decimals="INF" contextRef="c31" unitRef="usd">-0.13</us-gaap:EarningsPerShareDiluted>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo id="f593" decimals="0" contextRef="c3" unitRef="usd1">360000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="f594" xsi:nil="true" contextRef="c5" unitRef="shares"/>
  <us-gaap:NetIncomeLoss id="f595" decimals="0" contextRef="c54" unitRef="usd1">-2010824.0</us-gaap:NetIncomeLoss>
  <us-gaap:DividendsPreferredStock id="f596" decimals="0" contextRef="c12" unitRef="usd1">26133.0</us-gaap:DividendsPreferredStock>
  <vine:SecuredConvertiblePromissoryNotesOriginalIssueDiscountRate id="f597" decimals="INF" contextRef="c15" unitRef="pure">0.2</vine:SecuredConvertiblePromissoryNotesOriginalIssueDiscountRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f598" decimals="INF" contextRef="c13" unitRef="usd">8.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="f599" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="f600" contextRef="c5">&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zO2lkemagYeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zFqdeXYMtB23"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Companys accounting for fair value measurements
of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis
adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used
to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or
liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements).
The three levels of the fair value hierarchy are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify; text-indent: -0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify; text-indent: -0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify; text-indent: -0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The level in the fair value hierarchy within which
a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying values of cash, accounts receivable,
accounts payable, deferred revenue and other financial working capital items approximate fair value at September 30, 2024 and December
31, 2023, due to the short maturity nature of these items.&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f601" decimals="INF" contextRef="c5" unitRef="shares">17502861.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="f602" xsi:nil="true" contextRef="c5" unitRef="shares"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f603" decimals="0" contextRef="c10" unitRef="usd1">1626.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="f604" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHWzx5Heq3Ca" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrant activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_4B0_us-gaap--AwardTypeAxis_us-gaap--WarrantMember_zGJdCkCTnoTk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43A_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zDUOGWop4lzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 51%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;3,553,969&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj57EWuGYKLk"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_pip0_dtY_c20231231__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcdkwPhEmbf2"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zFYmt2dxMuXa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;744,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8CV1SmQbos2"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageRemainingContractualTerm_pip0_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2ePUcuHcwaj"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested or released&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_430_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_zxABwxIn8eBb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresWeightedAverageExercisePrice_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPUmK5E13cs5"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_432_c20240101__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_znuSn0C9ypy6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,997,969&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXXGpKrjsTzj"&gt;1.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_pip0_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYqk4QHgokWf"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="f605" contextRef="c5">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zkhrA1jEa1Zg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_828_zvf1aiVeVwp5"&gt;14. SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Securities Purchase
Agreements  Notes and Warrants&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On October 8, 2024, the Company
entered into Securities Purchase Agreements (the Securities Purchase Agreements) with two accredited investors, pursuant
to which the Company agreed to sell up to an aggregate principal amount of $&lt;span id="xdx_902_ecustom--SecuritiesPurchaseAgreementConvertibleNotePrincipalAmount_iI_c20241008_z1N3prvOlbZ6"&gt;600,000&lt;/span&gt; of secured convertible promissory notes (Notes)
that will be convertible into shares of the Companys common stock, par value $&lt;span id="xdx_90A_ecustom--SecuritiesPurchaseAgreementConvertibleNoteSharesParValue_iI_c20241008_zt3Q7QA1wXFa"&gt;0.001&lt;/span&gt;, and warrants (Warrants) to purchase
up to &lt;span id="xdx_909_ecustom--SecuritiesPurchaseAgreementConvertibleNoteWarrants_iI_c20241008_zhCIsc1kQ4Lb"&gt;740,000&lt;/span&gt; shares of common stock. The Company intends to use the proceeds for general corporate purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Notes were issued with
original issuance discount of &lt;span id="xdx_906_ecustom--SecuritiesPurchaseAgreementConvertibleNoteOriginalIssueDiscountRate_dp_c20241001__20241031_zXWbFh35c973"&gt;20&lt;/span&gt;%, resulting in gross proceeds of $&lt;span id="xdx_905_ecustom--GrossProceedsFromSecuritiesPurchaseAgreement_c20241001__20241031_zlf3voXdEEyi"&gt;500,000&lt;/span&gt; to the Company. The Company received $&lt;span id="xdx_903_ecustom--GrossProceedsFromSecuritiesPurchaseAgreement_c20240901__20240930_zRIyfk1RAzP5"&gt;300,000&lt;/span&gt; of the gross
proceeds as of September 30, 2024 and the Notes are reflected in Note 7. The Notes bear no interest unless an event of default occurs,
and mature on April 8, 2025. The Notes may be prepaid. Each Note is convertible into common stock at a conversion price equal to $&lt;span id="xdx_903_ecustom--SecuritiesPurchaseAgreementConvertibleNoteConversionPrice_c20241001__20241031_zlEhPSZBJPwb"&gt;0.40&lt;/span&gt;.
A holder of the Note (together with its affiliates) may not convert any portion of the Note to the extent that the holder would beneficially
own more than &lt;span id="xdx_904_ecustom--SecuritiesPurchaseAgreementConvertibleNoteMaximumOutstandingSharesOwnership_pip0_dp_c20241001__20241031_zTUOB3Acest4"&gt;9.99&lt;/span&gt;% of the outstanding shares of the Companys common stock immediately after exercise. The conversion price and
number of shares of the Companys common stock issuable upon conversion of the Notes will be subject to adjustment from time to
time for any subdivision or consolidation of shares, dilutive issuances and other events.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Additionally, the Notes are
secured by certain assets of the Company pursuant to a security agreement that was entered into in connection with the issuance of the
Notes (the Security Agreement). The obligations under the Notes are guaranteed by a guaranty (the Guaranty)
by the Company in favor of the investors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Warrants are immediately
exercisable at an initial exercise price equal to $&lt;span id="xdx_90A_ecustom--SecuritiesPurchaseAgreementConvertibleNoteWarrantsExercisePrice_c20241001__20241031_zjfTW80RbEEe"&gt;0.40&lt;/span&gt; per share, and will expire on the 5th anniversary of the issuance date. A holder
of the Warrant (together with its affiliates) may not exercise any portion of the Warrants to the extent that the holder would own more
than &lt;span id="xdx_90B_ecustom--SecuritiesPurchaseAgreementConvertibleNoteMaximumOutstandingSharesOwnership_pip0_dp_c20241001__20241031_zPIgz602nRv7"&gt;9.99&lt;/span&gt;% of the outstanding shares of the Companys common stock immediately after exercise. The exercise price and number of
shares of the Companys common stock issuable upon exercise of the Warrants will be subject to adjustment from time to time for
any subdivision or consolidation of shares, dilutive issuances and other events. The Warrants may not be exercised on a cashless basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Securities Purchase
Agreement  Series B Preferred Stock&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Companys
board of directors has approved the issuance and sale of up to approximately &lt;span id="xdx_90B_ecustom--SecuritiesPurchaseAgreementSeriesBPreferredStockShares_c20241001__20241105_zVkBzCGpX2ke"&gt;40,000&lt;/span&gt; shares of Series B Preferred Stock at a purchase
price of $&lt;span id="xdx_90E_ecustom--SecuritiesPurchaseAgreementSeriesBPreferredStockPurchasePricePerShare_c20241001__20241105_zLCD999W2kX9"&gt;100.00&lt;/span&gt; per share in a private placement. As of November 5, 2024, the Company has received securities purchase agreements
from accredited investors for the purchase of a total of &lt;span id="xdx_909_ecustom--SecuritiesPurchaseAgreementSeriesBPreferredStockTotalSharesAgreedToBePurchased_c20241001__20241105_zZe8dvv79rYj"&gt;40,865&lt;/span&gt; shares of Series B Stock for an aggregate purchase price of $&lt;span id="xdx_907_ecustom--SecuritiesPurchaseAgreementSeriesBPreferredStockTotalSharesAgreedToBePurchasedValue_pin6_c20241001__20241105_zK7lNJcCpZO6"&gt;4.1&lt;/span&gt;
million. The Company intends to use the proceeds to cover transaction expenses related to the proposed Business Combination (defined
below) and for general working capital purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Each share of Series B Preferred
Stock has the powers, designations, preferences, and other rights of the shares of such series as discussed in Note 8.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Secured Promissory
Notes Issued in favor of the Company&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company and Amaze
Software, Inc. (Amaze) entered into a promissory note (the Amaze Note) effective October 28, 2024, under
which the Company agreed to lend to Amaze the principal sum of up to $&lt;span id="xdx_90A_ecustom--PromissoryNotePrincipalLoanReceivableAmount_iI_pin6_c20241028_zPx60hxPHV4b"&gt;3.5&lt;/span&gt;
million. The Amaze Note bears interest at &lt;span id="xdx_90A_ecustom--PromissoryNoteInterestRatePerAnnum_iI_pip0_dp_c20241028__custom--MergerAxis__custom--MergerCompany1Member_zNobxF2AJ69i"&gt;6.00&lt;/span&gt;%
per annum until the closing date of the Business Combination (defined below). If the Business Combination does not close, the
interest rate increases to &lt;span id="xdx_905_ecustom--PromissoryNoteInterestRatePerAnnumIncrease_iI_dp_c20241028__custom--MergerAxis__custom--MergerCompany1Member_z3ugs7CleTW9"&gt;12&lt;/span&gt;%
per annum from the date that negotiations cease. The unpaid principal plus accrued interest is due and payable on the date that is &lt;span id="xdx_90F_ecustom--PromissoryNoteMaturityPeriodInEventOfMergerNotClosing_dtM_c20241001__20241031__custom--MergerAxis__custom--MergerCompany1Member_zv0Eosr2TZo9"&gt;9&lt;/span&gt;
months after the date on which the Company or Amaze provides notice to the other that negotiations have ceased if the Business
Combination is not closed. Provided there is no event of default, the Amaze note will be forgiven on the date the Business
Combination Agreement (detailed below) closes. The Amaze note is secured by all of the assets of its subsidiary, Amaze Holding
Company LLC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company and Adifex Holdings
LLC (Adifex) entered into a promissory note (the Adifex Note) effective October 7, 2024, under which the Company
agreed to lend to Adifex the principal sum of up to $&lt;span id="xdx_909_ecustom--PromissoryNotePrincipalLoanReceivableAmount_iI_pin6_c20241007__custom--MergerAxis__custom--MergerCompany2Member_z2toc1ak0Ku8"&gt;3.5&lt;/span&gt; million. The Adifex Note bears interest at &lt;span id="xdx_904_ecustom--PromissoryNoteInterestRatePerAnnum_iI_pip0_dp_c20241007__custom--MergerAxis__custom--MergerCompany2Member_zXYMsTZ7cRCk"&gt;6.00&lt;/span&gt;% per annum. In connection with
entering into the Amaze Note, the Company and Adifex cancelled and terminated the Adifex Note and the security agreement effective as
of October 7, 2024, between Adifex and the Company, pursuant to a Cancellation of Promissory Note and Security Agreement between the Company
and Adifex, effective October 28, 2024. As of October 28, 2024, the Company had made no advances, and no borrowings were outstanding,
under the Adifex Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Business Combination
Agreement with Adifex&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On November 3, 2024, the
Company entered into a Business Combination Agreement (the Business Combination Agreement) with (i) Amaze Holdings Inc.,
a Delaware corporation and a wholly owned subsidiary of the Company (Pubco), (ii) VINE Merger Sub Inc., a Delaware corporation
and wholly subsidiary of Pubco (&lt;i&gt;VINE Merger Sub&lt;/i&gt;), (iii) Adifex Merger Sub LLC, a Delaware limited liability company
and wholly owned subsidiary of Pubco (&lt;i&gt;Adifex Merger Sub&lt;/i&gt;), and (iv) Adifex Holdings LLC, a Delaware limited liability
company (&lt;i&gt;Adifex&lt;/i&gt;). The transactions contemplated by the Business Combination Agreement are referred to as the &lt;i&gt;Business
Combination&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Upon the closing of the Business
Combination, (i) VINE Merger Sub will merge with and into the Company (the VINE Merger), with the Company as the surviving
company in the VINE Merger and, as a result of the VINE Merger, the Company will become a wholly owned subsidiary of Pubco with holders
of the Companys equity interests receiving Pubco common stock, and (ii) Adifex Merger Sub will merge with and into Adifex (the
Adifex Merger), with Adifex as the surviving company in the Adifex Merger and, as a result of the Adifex Merger, Adifex
will become a wholly owned subsidiary of Pubco and the Adifex equity interests will be automatically converted into a pro rata portion
of the merger consideration in Pubco common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Business Combination
Agreement contains customary representations, warranties and covenants, including covenants obligating the Company, during the period
prior to closing, to conduct its business and operations in the ordinary course of business and not to engage in certain specified activities
without Adifexs prior consent.&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Consummation of the Business
Combination is subject to the satisfaction or waiver of certain closing conditions, including without limitation, approval by the Companys
stockholders of the Business Combination Agreement, including the Business Combination, completion of the acquisition of Amaze by Adifex,
and the Company having raised up to $&lt;span id="xdx_90F_ecustom--MaximumFundsToBeRaisedThroughEquitySalesAndDebtSecuritiesPursuantToBusinessCombinationAgreement_c20241001__20241114_zxMf6dfrSHT9"&gt;10,000,000&lt;/span&gt; through the sale of its equity or debt securities to cover transaction expenses and for
working capital purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Business Combination
Agreement may be terminated in certain limited circumstances including (i) by mutual written consent of the Company and Adifex; (ii) by
either the Company or Adifex if the VINE Merger and the Adifex Merger have not have been consummated by April 30, 2025 (subject to extension)
(iii) by either the Company or Adifex if a court of competent jurisdiction or governmental authority has issued a final and nonappealable
order, or taken any other action, having the effect of permanently restraining, enjoining, or otherwise prohibiting any of the transactions
contemplated by the Business Combination Agreement; (iv) by either the Company or Adifex upon a breach of any representation, warranty,
covenant, or agreement in the Business Combination Agreement by the other party; or (v) by the Company, upon the Companys board
of directors authorizing the Company to enter into a permitted alternative agreement in the manner set forth in the Business Combination
Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Sponsorship Settlement
Agreement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On October 8, 2024, the Company
settled in arbitration with WFI Stadium and Pro-Football LLC d/b/a Washington Commanders (together as the Commanders). The
Company paid $&lt;span id="xdx_903_ecustom--SponsorshipSettlementAgreementAmountsPaid_c20241001__20241114_zFxb4sQyBve9"&gt;80,000&lt;/span&gt; contemporaneously with the execution of the agreement, which was accrued for as of September 30, 2024. This resulted
in a $&lt;span id="xdx_905_ecustom--GainOnSettlementOfSponsorshipSettlementAgreementArbitration_c20241001__20241114_zthlpSKMTgC9"&gt;370,000&lt;/span&gt; gain on settlement, which will be recognized in the fourth quarter of 2024.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:CommonStockValue id="f606" decimals="0" contextRef="c3" unitRef="usd1">15976.0</us-gaap:CommonStockValue>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f607" decimals="0" contextRef="c56" unitRef="usd1">500.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
  <us-gaap:AdvertisingExpense id="f608" decimals="0" contextRef="c10" unitRef="usd1">7000.0</us-gaap:AdvertisingExpense>
  <vine:GrossProceedsFromSecuredConvertiblePromissoryNotes id="f609" decimals="0" contextRef="c15" unitRef="usd1">500000.0</vine:GrossProceedsFromSecuredConvertiblePromissoryNotes>
  <us-gaap:AccountsPayableCurrent id="f610" decimals="0" contextRef="c3" unitRef="usd1">1156937.0</us-gaap:AccountsPayableCurrent>
  <us-gaap:NetIncomeLoss id="f611" decimals="0" contextRef="c104" unitRef="usd1">-879569.0</us-gaap:NetIncomeLoss>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f612" decimals="INF" contextRef="c1" unitRef="shares">5905528.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <dei:EntityTaxIdentificationNumber id="f613" contextRef="c5">87-3905007</dei:EntityTaxIdentificationNumber>
  <us-gaap:UseOfEstimates id="f614" contextRef="c5">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zDodCWEtL3Ai" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zQ0RJMLtv7l4"&gt;Accounting Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management uses estimates and assumptions in preparing
these financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates.
Significant items subject to such estimates and assumptions include allowance for doubtful accounts, allowance for inventory obsolescence,
equity-based compensation for employees and non-employees, and the valuation of deferred tax assets.&lt;/p&gt;

</us-gaap:UseOfEstimates>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets id="f615" decimals="0" contextRef="c173" unitRef="usd1">400000.0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockholdersEquity id="f616" decimals="0" contextRef="c162" unitRef="usd1">15876.0</us-gaap:StockholdersEquity>
  <vine:SecuredConvertiblePromissoryNotesConversionPriceCommonStock id="f617" decimals="INF" contextRef="c15" unitRef="usd">0.4</vine:SecuredConvertiblePromissoryNotesConversionPriceCommonStock>
  <us-gaap:AssetsCurrent id="f618" decimals="0" contextRef="c13" unitRef="usd1">889257.0</us-gaap:AssetsCurrent>
  <us-gaap:InventoryDisclosureTextBlock id="f619" contextRef="c5">&lt;p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zYuNKZhetzRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_824_zp50WZKPFRPb"&gt;3. INVENTORIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventory is primarily bottled wine which is
carried at the lower cost (calculated using the average cost method) or net realizable value. The Company increased the inventory
allowance by approximately $&lt;span id="xdx_907_ecustom--IncreaseInventoryAllowance_c20230101__20230930_z7Y0U7VBNPg9"&gt;209,000&lt;/span&gt;
during the nine months ended September 30, 2023. This write down was recorded in cost of revenue in the financial statements. During
the first six months of the 2024 fiscal year, the Company recorded an allowance of approximately $&lt;span id="xdx_90D_ecustom--GainOnInventoryReserve_c20240701__20240930_zGkwIRnGM8ll"&gt;154,000&lt;/span&gt;.
However, in the quarter ended September 30, 2024, this allowance was reversed, and the reversal was recorded as a gain from recovery
of inventory reserve. The finished goods inventory was approximately $&lt;span id="xdx_903_eus-gaap--InventoryFinishedGoods_iI_c20240930_zTZ94rNdNxo3"&gt;233,000 &lt;/span&gt;and
$&lt;span id="xdx_904_eus-gaap--InventoryFinishedGoods_iI_c20231231_zvfTzdf9GTci"&gt;338,000&lt;/span&gt; as of September 30, 2024 and December
31, 2023, respectively. This inventory included a valuation reserve of approximately $&lt;span id="xdx_90A_eus-gaap--InventoryValuationReserves_iI_c20240930_zfNLGqnIzKE1"&gt;0 &lt;/span&gt;and
$&lt;span id="xdx_905_eus-gaap--InventoryValuationReserves_iI_c20231231_zhleoHcniDz"&gt;112,000&lt;/span&gt; as of September 30, 2024 and
December 31, 2023, respectively.&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:SharesOutstanding id="f620" decimals="INF" contextRef="c174" unitRef="shares">15976227.0</us-gaap:SharesOutstanding>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f621" decimals="INF" contextRef="c3" unitRef="shares">300000.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="f622" decimals="INF" contextRef="c175" unitRef="shares">20000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:SharesOutstanding id="f623" decimals="INF" contextRef="c176" unitRef="shares">15976227.0</us-gaap:SharesOutstanding>
  <us-gaap:TemporaryEquitySharesSubscribedButUnissued id="f624" decimals="INF" contextRef="c136" unitRef="shares">6366129.0</us-gaap:TemporaryEquitySharesSubscribedButUnissued>
  <us-gaap:Assets id="f625" decimals="0" contextRef="c3" unitRef="usd1">981763.0</us-gaap:Assets>
  <us-gaap:Revenues id="f626" decimals="0" contextRef="c177" unitRef="usd1">1192138.0</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss id="f627" decimals="0" contextRef="c5" unitRef="usd1">-2407174.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited id="f628" decimals="INF" contextRef="c80" unitRef="shares">1041331.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
  <vine:ProceedsFromSecuredConvertiblePromissoryNotes id="f629" decimals="0" contextRef="c20" unitRef="usd1">300000.0</vine:ProceedsFromSecuredConvertiblePromissoryNotes>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="f630" decimals="INF" contextRef="c32" unitRef="shares">500000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="f631" decimals="0" contextRef="c5" unitRef="usd1">209085.0</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:ScheduleOfDebtTableTextBlock id="f632" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zwCOQx32RMCb" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of the Company's outstanding debts (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240930_zWU12W6va5G5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_490_20231231_zrSrxkrbhuO" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_zmJiZBJD8rng" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;Convertible notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_zQi2fQQuRKw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: discount on convertible notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(185,031&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ConvertibleNotesPayableCurrent_iI_zoolLujESBd7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total convertible notes, net of discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;174,969&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0763"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherNotesPayableCurrent_iI_zt5a4Ugxhtm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Other note payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NotesPayableCurrent_iI_zfQpDJZti5Gk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;202,469&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="f633" decimals="0" contextRef="c5" unitRef="usd1">-2513307.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f634" decimals="INF" contextRef="c178" unitRef="usd">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:SharesOutstanding id="f635" decimals="INF" contextRef="c89" unitRef="shares">15976227.0</us-gaap:SharesOutstanding>
  <us-gaap:InventoryNet id="f636" decimals="0" contextRef="c3" unitRef="usd1">232826.0</us-gaap:InventoryNet>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited id="f637" decimals="INF" contextRef="c179" unitRef="shares">970000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock id="f638" contextRef="c5">&lt;p id="xdx_843_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9f6KRCnpws7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_ztC7kXI1VqIg"&gt;Liquidity, Going Concern, and Management
Plan&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Historically, the Company has incurred losses, which
has resulted in an accumulated deficit of approximately $&lt;span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_dxL_c20240930_znhUgVKwdXi" title="::XDX::-28990067"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0588"&gt;29.0&lt;/span&gt;&lt;/span&gt;million as of September 30, 2024. Cash flows used in operating activities
were approximately $&lt;span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_dxL_c20240101__20240930_zrT2lLhE7h31" title="::XDX::-1346789"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0589"&gt;1.3&lt;/span&gt;&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_dxL_c20230101__20230930_zELPqVKeSNo8" title="::XDX::-4585403"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0590"&gt;4.6&lt;/span&gt;&lt;/span&gt;million for the nine months ended September 30, 2024 and 2023, respectively. As of September
30, 2024, the Company had an approximately $&lt;span id="xdx_907_ecustom--WorkingCapital_iNI_pin6_di_c20240930_zxmIZsHz3yE1"&gt;2.9&lt;/span&gt;million working capital deficit, inclusive of approximately $&lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_dxL_c20240930_z6MpOGYBMvV2" title="::XDX::72029"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0592"&gt;72,000&lt;/span&gt;&lt;/span&gt;in cash
and $&lt;span id="xdx_907_eus-gaap--RestrictedCashCurrent_iI_dxL_c20240930_zMIZNIPUnmDh" title="::XDX::50039"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;50,000&lt;/span&gt;&lt;/span&gt;in restricted cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Companys ability to continue as a going
concern is dependent on its ability to meet its liquidity needs through a combination of factors including but not limited to, cash and
cash equivalents, working capital and strategic capital raises. The ultimate success of these plans is not guaranteed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In considering our forecast for the next twelve months
and the current cash and working capital as of the filing of this Form 10-Q, such matters create a substantial doubt regarding the Companys
ability to meet their financial needs and continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company received gross proceeds of
approximately $&lt;span id="xdx_906_ecustom--GrossProceedsFromSaleOfPreferredStock_c20240101__20240630_z9qvzXzBGw1"&gt;914,000&lt;/span&gt; and
$&lt;span id="xdx_90D_ecustom--GrossProceedsFromSaleOfPreferredStock_pn6n6_c20230101__20231231_zsPkHSGlpiyg"&gt;1&lt;/span&gt; millionfrom
preferred stock offerings during the periods ended June 30, 2024 and December 31, 2023, respectively. During the quarter ended
September 30, 2024, the Company received $&lt;span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_c20240701__20240930_zY6lzUaNhDZg"&gt;300,000&lt;/span&gt;
from the issuance of convertible notes. Subsequent to September 30, 2024, the Company raised approximately $&lt;span id="xdx_908_ecustom--GrossProceedsFromSaleOfPreferredStock_pin6_c20241001__20241114_zJ1uXEM1Tmnj"&gt;4.1&lt;/span&gt;
million from the sale of preferred stock, received an additional $&lt;span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20241001__20241114_zOVFPWVJwVT8"&gt;200,000&lt;/span&gt;
from the issuance of convertible notes and entered into a Business Combination Agreement (See Note 14 for further details). In
addition, under the Business Combination Agreement (as defined below), the Company has agreed to raise up to $&lt;span id="xdx_90C_ecustom--MaximumFundsToBeRaisedThroughEquitySalesAndDebtSecuritiesPursuantToBusinessCombinationAgreement_c20241001__20241114_zzdqHcT94IF5"&gt;10,000,000&lt;/span&gt;
through the sale of its equity or debt securities to cover transaction expenses and for working capital purposes, and the completion
of such funding is a condition precedent to completing the Business Combination (as defined below). In addition, the Company will
need additional debt or equity financing to sustain existing operations. If adequate financing is not available, the Company will be
forced to take measures to severely reduce our expenses and business operations or discontinue them completely. Such financing, if
available, may be dilutive. At the current reduced pace of incurring expenses and with receipt of additional financing and the
receipt of proceeds from the expected sales of inventory, the Company projects that the existing cash balance will be sufficient to
fund current operations into the first quarter of 2025, after which additional financing or capital will be needed to satisfy
obligations. Additional financing may not be available on favorable terms or at all. If additional financing is available, it may be
highly dilutive to existing shareholders and may otherwise include burdensome or onerous terms. The Companys inability to
raise additional working capital in a timely manner would negatively impact the ability to fund operations, generate revenues,
maintain or grow the business and otherwise execute the Companys business plan, leading to the reduction or suspension of
operations and ultimately potentially ceasing operations altogether and initiating bankruptcy proceedings. Should this occur, the
value of any investment in the Companys securities would be adversely affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These factors raise substantial doubt about the Companys
ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification
of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue
as a going concern.&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
  <us-gaap:DividendsPreferredStock id="f639" decimals="0" contextRef="c86" unitRef="usd1">50000.0</us-gaap:DividendsPreferredStock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="f640" contextRef="c5">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zE1ng1GRGw8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="xdx_822_zQOOSxSCttOh"&gt;1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NatureOfOperations_zPfzuu03vM67" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_ztOuWmJObHt5"&gt;Nature of Business&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fresh Vine Wine, Inc. (the Company,
our, we), a Nevada corporation, is a premium wine brand built to complement consumers healthy and active
lifestyles. The Company provides a competitively priced premium product that is blended to deliver several important benefits, such as
low-cal, low-sugar, low-carb. The Companys wines are also gluten-free and keto and vegan friendly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Companys revenue is comprised primarily
of wholesale and direct to consumer (DTC) sales, and representation and distribution services. Wholesale revenue is generated through
sales to distributors located in states throughout the United States of America. DTC revenue is generated from individuals purchasing
wine directly from the Company through club membership and the Companys website.&lt;/p&gt;

&lt;p id="xdx_856_z0zuD4PBlgjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zra9he1Q0wza" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zOrT1eD2ql69"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Companys financial statements have been
prepared and are presented in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial
statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair presentation
of the financial statements. In certain instances, amounts reported in prior period financial statements have been reclassified to conform
to the current financial statement presentation.&lt;/p&gt;

&lt;p id="xdx_858_zrptb8dpBBv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--TerminationOfAgreementAndPlanOfMergerPolicyTextBlock_zbB2bM8Wjpsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_z5iuOZValBk9"&gt;Termination of Agreement and Plan of Merger
with Notes Live&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 25, 2024,the Company, FVW Merger
Sub, Inc., a Colorado corporation and a wholly-owned subsidiary ofthe Company(Merger Sub), and Notes, Live,
Inc., a Colorado corporation (Notes Live), entered into an Agreement and Plan of Merger (the Merger Agreement)
pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement,
Merger Sub will merge with and into Notes Live, with Notes Live continuing as a wholly-owned subsidiary of the Company and the surviving
corporation of the merger (the Merger). On July 31, 2024, the Merger Agreement was terminated.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_85A_zLDXNKlmk97a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9f6KRCnpws7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_ztC7kXI1VqIg"&gt;Liquidity, Going Concern, and Management
Plan&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Historically, the Company has incurred losses, which
has resulted in an accumulated deficit of approximately $&lt;span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_dxL_c20240930_znhUgVKwdXi" title="::XDX::-28990067"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0588"&gt;29.0&lt;/span&gt;&lt;/span&gt;million as of September 30, 2024. Cash flows used in operating activities
were approximately $&lt;span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_dxL_c20240101__20240930_zrT2lLhE7h31" title="::XDX::-1346789"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0589"&gt;1.3&lt;/span&gt;&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_dxL_c20230101__20230930_zELPqVKeSNo8" title="::XDX::-4585403"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0590"&gt;4.6&lt;/span&gt;&lt;/span&gt;million for the nine months ended September 30, 2024 and 2023, respectively. As of September
30, 2024, the Company had an approximately $&lt;span id="xdx_907_ecustom--WorkingCapital_iNI_pin6_di_c20240930_zxmIZsHz3yE1"&gt;2.9&lt;/span&gt;million working capital deficit, inclusive of approximately $&lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_dxL_c20240930_z6MpOGYBMvV2" title="::XDX::72029"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0592"&gt;72,000&lt;/span&gt;&lt;/span&gt;in cash
and $&lt;span id="xdx_907_eus-gaap--RestrictedCashCurrent_iI_dxL_c20240930_zMIZNIPUnmDh" title="::XDX::50039"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;50,000&lt;/span&gt;&lt;/span&gt;in restricted cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Companys ability to continue as a going
concern is dependent on its ability to meet its liquidity needs through a combination of factors including but not limited to, cash and
cash equivalents, working capital and strategic capital raises. The ultimate success of these plans is not guaranteed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In considering our forecast for the next twelve months
and the current cash and working capital as of the filing of this Form 10-Q, such matters create a substantial doubt regarding the Companys
ability to meet their financial needs and continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company received gross proceeds of
approximately $&lt;span id="xdx_906_ecustom--GrossProceedsFromSaleOfPreferredStock_c20240101__20240630_z9qvzXzBGw1"&gt;914,000&lt;/span&gt; and
$&lt;span id="xdx_90D_ecustom--GrossProceedsFromSaleOfPreferredStock_pn6n6_c20230101__20231231_zsPkHSGlpiyg"&gt;1&lt;/span&gt; millionfrom
preferred stock offerings during the periods ended June 30, 2024 and December 31, 2023, respectively. During the quarter ended
September 30, 2024, the Company received $&lt;span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_c20240701__20240930_zY6lzUaNhDZg"&gt;300,000&lt;/span&gt;
from the issuance of convertible notes. Subsequent to September 30, 2024, the Company raised approximately $&lt;span id="xdx_908_ecustom--GrossProceedsFromSaleOfPreferredStock_pin6_c20241001__20241114_zJ1uXEM1Tmnj"&gt;4.1&lt;/span&gt;
million from the sale of preferred stock, received an additional $&lt;span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20241001__20241114_zOVFPWVJwVT8"&gt;200,000&lt;/span&gt;
from the issuance of convertible notes and entered into a Business Combination Agreement (See Note 14 for further details). In
addition, under the Business Combination Agreement (as defined below), the Company has agreed to raise up to $&lt;span id="xdx_90C_ecustom--MaximumFundsToBeRaisedThroughEquitySalesAndDebtSecuritiesPursuantToBusinessCombinationAgreement_c20241001__20241114_zzdqHcT94IF5"&gt;10,000,000&lt;/span&gt;
through the sale of its equity or debt securities to cover transaction expenses and for working capital purposes, and the completion
of such funding is a condition precedent to completing the Business Combination (as defined below). In addition, the Company will
need additional debt or equity financing to sustain existing operations. If adequate financing is not available, the Company will be
forced to take measures to severely reduce our expenses and business operations or discontinue them completely. Such financing, if
available, may be dilutive. At the current reduced pace of incurring expenses and with receipt of additional financing and the
receipt of proceeds from the expected sales of inventory, the Company projects that the existing cash balance will be sufficient to
fund current operations into the first quarter of 2025, after which additional financing or capital will be needed to satisfy
obligations. Additional financing may not be available on favorable terms or at all. If additional financing is available, it may be
highly dilutive to existing shareholders and may otherwise include burdensome or onerous terms. The Companys inability to
raise additional working capital in a timely manner would negatively impact the ability to fund operations, generate revenues,
maintain or grow the business and otherwise execute the Companys business plan, leading to the reduction or suspension of
operations and ultimately potentially ceasing operations altogether and initiating bankruptcy proceedings. Should this occur, the
value of any investment in the Companys securities would be adversely affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These factors raise substantial doubt about the Companys
ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification
of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue
as a going concern.&lt;/p&gt;

&lt;p id="xdx_85E_zpkW7o3soEkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zDodCWEtL3Ai" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zQ0RJMLtv7l4"&gt;Accounting Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management uses estimates and assumptions in preparing
these financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates.
Significant items subject to such estimates and assumptions include allowance for doubtful accounts, allowance for inventory obsolescence,
equity-based compensation for employees and non-employees, and the valuation of deferred tax assets.&lt;/p&gt;

&lt;p id="xdx_851_zkuWhy0ps22" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zXZ51HvFbtF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zRhav6b8ICZb"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains its accounts at two financial
institutions. At times throughout the year, the Companys cash balances may exceed amounts insured by the Federal Deposit Insurance
Corporation. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.&lt;/p&gt;

&lt;p id="xdx_85D_zkWROdA74tKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zZ5koyrm6wWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zKVyx2kOTk69"&gt;Restricted Cash&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Included in the cash balance is a balance of approximately
$&lt;span id="xdx_906_eus-gaap--RestrictedCashCurrent_iI_dxL_c20240930_zl7nBjhhLDvj" title="::XDX::50039"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0606"&gt;50,000&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--RestrictedCashCurrent_iI_c20231231_zEs72MdcA0O6"&gt;100,000&lt;/span&gt; as of September 30, 2024 and December 31, 2023, respectively, that the Companys operating bank has required
us to maintain as a security for collectability of automated clearing house transactions. These funds are held in a separate account and
are not available for disbursements.&lt;/p&gt;

&lt;p id="xdx_858_zvhotSgYpQ48" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zczhzgadi3N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zbo1Ju9lNbhl"&gt;Accounts Receivable&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable consists of amounts owed to the
Company for sales of the Companys products on credit and are reported at net realizable value. Credit terms are extended to customers
in the normal course of business. The Company performs ongoing credit evaluations of its customers financial conditions. The Company
estimates allowances for future returns and doubtful accounts based upon historical experience and its evaluation of the current status
of receivables. Accounts considered uncollectible are written off against the allowance. As of September 30, 2024 and December 31, 2023
there was no allowance for doubtful accounts.&lt;/p&gt;

&lt;p id="xdx_85E_zQkXtffEuQzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zfzbaprInle5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zNbxOgX5TCFe"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories primarily include bottled wine which is
carried at the lower of cost (calculated using theaverage cost method) or net realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reduces the carrying value of inventories
that are obsolete or for which market conditions indicate cost will not be recovered to estimated net realizable value. The Companys
estimate of net realizable value is based on analysis and assumptions including, but not limited to, historical experience, future demand,
and market requirements. Reductions to the carrying value of inventories are recorded in cost of revenues.As of September 30, 2024
and December 31, 2023, the Company had recorded an inventory allowance of approximately $&lt;span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_c20240930_zB06j1bVUfe7"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_c20231231_zU7UwmT31BC5"&gt;112,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p id="xdx_854_z4YGccRWxaV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--InvestmentPolicyTextBlock_zIZHwbd0YbB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z0n7LaaQlsu3"&gt;Investment in Equity Securities&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity investments that do not provide the Company
the ability to exert significant influence over the operating or financial decisions of the investee are accounted for under the measurement
alternative for non-marketable equity securities under ASC 321 Investments  Equity Securities. In accordance with ASC 321, the
non-marketable equity securities are initially measured at cost and reviewed at year end for impairment and fair value changes. As of
September 30, 2024, there were no changes recorded for the value of the investment since the initial measurement.&lt;/p&gt;

&lt;p id="xdx_852_z3fFntlqz0hf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z1eTg6ylUP7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zHbfUY0bniB9"&gt;Revenue recognition&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Companys total
revenue reflects the sale of wine domestically in the U.S. to wholesale distributors or DTC customers. Under ASC Topic 606,&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;(ASC 606), the Company recognizes revenue when control of the promised good is transferred
to the customer in an amount that reflects the consideration for which the Company is expected to be entitled to receive in exchange for
those products. Each contract includes a single performance obligation to transfer control of the product to the customer. Control is
transferred when the product is either shipped or delivered, depending on the shipping terms, at which point the Company recognizes the
transaction price for the product as revenue. The Company has elected to account for shipping and handling as a fulfillment activity,
with amounts billed to customers for shipping and handling included in total revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company also generates
revenue through membership in its wine club. Wine club members pay a monthly fee, which varies depending on level of membership, and are
entitled to receive quarterly shipments of wine, free shipping, and discounts on other wine and merchandise purchased. The Company recognizes
revenue for the monthly membership dues when the product is delivered. Any membership dues received before the product is delivered is
recorded as deferred revenue on the Companys balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;ASC 606 notes that when another
party is involved in providing goods or services to acustomer, the entity should determine whether the nature of its promise is
aperformance obligationto provide the specified goods or services itself (that is, the entity is a principal) or to arrange
for those goods or services to be provided by the other party (that is, the entity is an agent).The Company does not bear responsibility
for inventory losses and does not have pricing determination; therefore, the Company would be considered the agent and revenue should
be recognized as net sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Products are sold for cash or on credit terms. Credit
terms are established in accordance with local and industry practices, and typically require payment within 30-60 days of delivery or
shipment, as dictated by the terms of each agreement. The Company has elected the practical expedient to not account for significant financing
components as its payment terms are less than one year, and the Company determines the terms at contract inception. The Companys
sales terms do not allow for the right of return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The following table presents
the percentages of total revenue disaggregated by sales channels for the three and nine months ended September 30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--DisaggregationOfRevenueTableTextBlock_zN7gai0phEHi" style="font: 11pt Aptos; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Percentages of total revenue disaggregated by sales channels (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three months ended&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nine months ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%"&gt;Wholesale&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zHYqeVqRPaC2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;12.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zgAFI1it8t6h" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;87.8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_ze5cXGNEq8N6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;16.8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__custom--WholesaleConcentrationRiskMember_zJQepgzTwEda" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;75.1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Direct to consumer&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJXLSVk3nMn7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;87.7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpKaDWLgVk59" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z0DB2aexn1dj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwvplope6jV" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;24.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zKqmk03Ur8s8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zAdgsp416ha4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zimSnritT8pk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zjyhoOLYdSNd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zdNycTM1I64e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 5pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85B_ztKVyXWR3421" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 5pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zO2lkemagYeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zFqdeXYMtB23"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Companys accounting for fair value measurements
of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis
adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used
to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or
liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements).
The three levels of the fair value hierarchy are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify; text-indent: -0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify; text-indent: -0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify; text-indent: -0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The level in the fair value hierarchy within which
a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying values of cash, accounts receivable,
accounts payable, deferred revenue and other financial working capital items approximate fair value at September 30, 2024 and December
31, 2023, due to the short maturity nature of these items.&lt;/p&gt;

&lt;p id="xdx_855_zSTiqVsQmElk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zMyorY0XDiI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zE7CcfhJlGf9"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes uncertain tax positions in
accordance with ASC 740 on the basis of evaluating whether it is more likely than not that the tax positions will be sustained upon examination
by tax authorities. For those tax positions that meet the more-likely-than not recognition threshold, the Company recognizes the largest
amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement. The Company recognizes interest and/or
penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of September 30, 2024 or
December 31, 2023, and as such, no interest or penalties were recorded to income tax expense. As of September 30, 2024 and December 31,
2023, the Company has no unrecognized tax benefits. There are no unrecognized tax benefits included on the balance sheet that would, if
recognized, impact the effective tax rate. The Company does not anticipate there will be a significant change in unrecognized tax benefits
within the next 12 months.&lt;/p&gt;

&lt;p id="xdx_85A_z5aAqKPYv3vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zrNbfe5cOAE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zlq0M7aNkHd6"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company measures equity-based compensation cost
at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which
is generally the vesting period. The Company recognizes any forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company measures equity-based compensation when
the service inception date precedes the grant date based on the fair value of the award as an accrual of equity-based compensation and
adjusts the cost to fair value at each reporting date prior to the grant date. In the period in which the grant occurs, the cumulative
compensation cost is adjusted to the fair value at the date of the grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;See Note 9 for further discussion of equity-based
compensation incurred in 2024 and 2023.&lt;/p&gt;

&lt;p id="xdx_85E_zUnPojRW5u02" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_z4ecroRc39R6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zK9ulM3gKjpc"&gt;Advertising&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the costs of advertising as incurred.
Advertising expenses were approximately $&lt;span id="xdx_90C_eus-gaap--AdvertisingExpense_c20240701__20240930_zfRkOpCu1OTa"&gt;7,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AdvertisingExpense_c20230701__20230930_zgsdtDwJsF55"&gt;258,000&lt;/span&gt; for the three months ended September 30, 2024 and 2023, respectively and was
approximately $&lt;span id="xdx_903_eus-gaap--AdvertisingExpense_c20240101__20240930_zUjoYyCMqfPd"&gt;334,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AdvertisingExpense_pin6_c20230101__20230930_zP00tGyPMC4g"&gt;1.4&lt;/span&gt; million for the nine months ended September 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p id="xdx_856_zMFPdzWPLtO" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhtXokoxSjJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zqYvL0LtpBvb"&gt;Application of New or Revised Accounting
Standards&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Jumpstart Our Business Startups Act
of 2012 (the JOBS Act), a company constituting an emerging growth company is, among other things, entitled
to rely upon certain reduced reporting requirements and is eligible to take advantage of an extended transition period to comply with
new or revised accounting standards applicable to public companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is an emerging growth company and has
elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates
for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively
and irrevocable opts out of the extended transition period provide in the JOBS Act.&lt;/p&gt;

&lt;p id="xdx_85A_zzJT7lgS7fZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--NYSEListingRequirementPolicyPolicyTextBlock_zBhHhpXVS0D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zsNbkbccVOu2"&gt;NYSE Listing Requirements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 8, 2023, the Company received a written
notice (the Notice) from NYSE American stating that it was not in compliance with Section 1003(a)(ii) of the NYSE American
Company Guide (the Company Guide), which requires a listed company that has reported losses from continuing operations and/or
net losses in three of its four most recent fiscal years to maintain at least $&lt;span id="xdx_90F_eus-gaap--StockholdersEquityOther_pn6n6_c20230908__20230908_zs4nw30z5Ix7"&gt;4&lt;/span&gt;million of stockholders equity. The Company
reported stockholders deficit of approximately $&lt;span id="xdx_909_eus-gaap--StockholdersEquity_iI_dxL_c20240930_znEQweZmpZIf" title="::XDX::-2401579%09"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;2.4&lt;/span&gt;&lt;/span&gt; million as of September 30, 2024 and have had losses from continuing operations
and/or net losses in each of the fiscal years ended December 31, 2020, 2021, 2022 and 2023. As required by the NYSE American, the Company
submitted a plan to the NYSE American on October 9, 2023 addressing actions it has taken and how it intends to regain compliance with
the continued listing standards within the required 18 month period ending March 8, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 21, 2023, the Company received notification
(the Acceptance Letter) from NYSE American that the Companys plan to regain compliance with NYSE Americans
listing standards was accepted.The Acceptance Letter also stated that the Company is not in compliance with Section 1003(a)(i) of
the Company Guide, which requires an issuer to have stockholders equity of $&lt;span id="xdx_90E_eus-gaap--StockholdersEquityOther_pin6_c20231101__20231121_z7960T8Y2Jh1"&gt;2.0&lt;/span&gt; million or more if it has reported losses from
continuing operations and/or net losses in two out of its three most recent fiscal years. NYSE American has granted the Company a plan
period through March 8, 2025 to regain compliance with Sections 1003(a)(i) and (ii) of the Company Guide. If the Company is not in compliance
with all continued listing standards by that date or if the Company does not make progress consistent with the plan during the plan period,
the Company will be subject to delisting proceedings.&lt;/p&gt;

&lt;p id="xdx_85F_zlF8oroffvI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 5pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f641" decimals="INF" contextRef="c180" unitRef="shares">970000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EarningsPerShareDiluted id="f642" decimals="INF" contextRef="c5" unitRef="usd">-0.15</us-gaap:EarningsPerShareDiluted>
  <vine:WarrantsIssuedPursuantToSecuritiesPurchaseAgreements id="f643" decimals="INF" contextRef="c15" unitRef="shares">740000.0</vine:WarrantsIssuedPursuantToSecuritiesPurchaseAgreements>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f644" decimals="INF" contextRef="c136" unitRef="usd">1.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets id="f645" decimals="INF" contextRef="c173" unitRef="shares">4000.0</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f646" decimals="INF" contextRef="c179" unitRef="shares">1030000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <vine:WarrantsIssuedPursuantToSecuritiesPurchaseAgreementsExercisePrice id="f647" decimals="INF" contextRef="c15" unitRef="usd">0.4</vine:WarrantsIssuedPursuantToSecuritiesPurchaseAgreementsExercisePrice>
  <dei:DocumentPeriodEndDate id="f648" contextRef="c5">2024-09-30</dei:DocumentPeriodEndDate>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f649" decimals="0" contextRef="c31" unitRef="usd1">111748.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f650" decimals="0" contextRef="c28" unitRef="usd1">90325.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <vine:IncreaseInventoryAllowance id="f651" decimals="0" contextRef="c1" unitRef="usd1">209000.0</vine:IncreaseInventoryAllowance>
  <vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued id="f652" decimals="0" contextRef="c54" unitRef="usd1">2546728.0</vine:StockIssuedDuringPeriodValueRightsOfferingCommonStockAndWarrantsIssued>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f653" decimals="0" contextRef="c152" unitRef="usd1">374178.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f654" decimals="0" contextRef="c83" unitRef="usd1">1625.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <vine:StockholderReceivedSubscriptionRights id="f655" decimals="INF" contextRef="c181" unitRef="shares">0.5</vine:StockholderReceivedSubscriptionRights>
  <us-gaap:AccountsPayableCurrent id="f656" decimals="0" contextRef="c13" unitRef="usd1">509337.0</us-gaap:AccountsPayableCurrent>
  <us-gaap:NetIncomeLoss id="f657" decimals="0" contextRef="c12" unitRef="usd1">-879569.0</us-gaap:NetIncomeLoss>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="f658" decimals="INF" contextRef="c5" unitRef="shares">1666.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="f659" contextRef="c5">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zXZ51HvFbtF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zRhav6b8ICZb"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains its accounts at two financial
institutions. At times throughout the year, the Companys cash balances may exceed amounts insured by the Federal Deposit Insurance
Corporation. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:InventoryValuationReserves id="f660" decimals="0" contextRef="c3" unitRef="usd1">0.0</us-gaap:InventoryValuationReserves>
  <us-gaap:StockholdersEquity id="f661" decimals="0" contextRef="c182" unitRef="usd1">24221988.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f662" decimals="0" contextRef="c107" unitRef="usd1">1626.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <vine:GainOnInventoryReserve id="f663" decimals="0" contextRef="c10" unitRef="usd1">154000.0</vine:GainOnInventoryReserve>
  <us-gaap:PreferredStockConvertibleConversionPrice id="f664" decimals="INF" contextRef="c3" unitRef="usd">0.05</us-gaap:PreferredStockConvertibleConversionPrice>
  <vine:SecuritiesPurchaseAgreementConvertibleNotePrincipalAmount id="f665" decimals="0" contextRef="c2" unitRef="usd1">600000.0</vine:SecuritiesPurchaseAgreementConvertibleNotePrincipalAmount>
  <vine:StockholdersSubscriptionPerShare id="f666" decimals="INF" contextRef="c181" unitRef="usd">1.0</vine:StockholdersSubscriptionPerShare>
  <us-gaap:NetIncomeLoss id="f667" decimals="0" contextRef="c10" unitRef="usd1">-315290.0</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="f668" decimals="0" contextRef="c5" unitRef="usd1">-722.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:StockholdersEquity id="f669" decimals="0" contextRef="c174" unitRef="usd1">15976.0</us-gaap:StockholdersEquity>
  <vine:NetExpenseRelatingToAgreements id="f670" decimals="0" contextRef="c183" unitRef="usd1">0.0</vine:NetExpenseRelatingToAgreements>
  <us-gaap:StockholdersEquity id="f671" decimals="0" contextRef="c176" unitRef="usd1">15976.0</us-gaap:StockholdersEquity>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="f672" decimals="0" contextRef="c121" unitRef="usd1">131353.0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:InventoryValuationReserves id="f673" decimals="0" contextRef="c13" unitRef="usd1">112000.0</us-gaap:InventoryValuationReserves>
  <us-gaap:OtherPrepaidExpenseCurrent id="f674" decimals="0" contextRef="c13" unitRef="usd1">9871.0</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="f675" decimals="0" contextRef="c80" unitRef="usd1">-1041.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
  <us-gaap:InventoryWriteDown id="f676" decimals="0" contextRef="c1" unitRef="usd1">1732500.0</us-gaap:InventoryWriteDown>
  <us-gaap:InventoryFinishedGoods id="f677" decimals="0" contextRef="c3" unitRef="usd1">233000.0</us-gaap:InventoryFinishedGoods>
  <vine:SponsorshipAgreementsCurrent id="f678" decimals="0" contextRef="c3" unitRef="usd1">832660.0</vine:SponsorshipAgreementsCurrent>
  <vine:SecuritiesPurchaseAgreementConvertibleNoteSharesParValue id="f679" decimals="INF" contextRef="c2" unitRef="usd">0.001</vine:SecuritiesPurchaseAgreementConvertibleNoteSharesParValue>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f680" decimals="0" contextRef="c32" unitRef="usd1">500.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f681" decimals="0" contextRef="c184" unitRef="usd1">3143969.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="f682" decimals="0" contextRef="c1" unitRef="usd1">227036.0</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="f683" decimals="0" contextRef="c1" unitRef="usd1">-8578381.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <vine:NetExpenseRelatingToAgreements id="f684" decimals="0" contextRef="c185" unitRef="usd1">89333.0</vine:NetExpenseRelatingToAgreements>
  <us-gaap:InvestmentPolicyTextBlock id="f685" contextRef="c5">&lt;p id="xdx_84C_eus-gaap--InvestmentPolicyTextBlock_zIZHwbd0YbB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z0n7LaaQlsu3"&gt;Investment in Equity Securities&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity investments that do not provide the Company
the ability to exert significant influence over the operating or financial decisions of the investee are accounted for under the measurement
alternative for non-marketable equity securities under ASC 321 Investments  Equity Securities. In accordance with ASC 321, the
non-marketable equity securities are initially measured at cost and reviewed at year end for impairment and fair value changes. As of
September 30, 2024, there were no changes recorded for the value of the investment since the initial measurement.&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
  <dei:LocalPhoneNumber id="f686" contextRef="c5">766-9463</dei:LocalPhoneNumber>
</xbrli:xbrl>
